

US008865158B2

(12) **United States Patent**
Qimron et al.

(10) **Patent No.:** **US 8,865,158 B2**
(45) **Date of Patent:** **Oct. 21, 2014**

(54) **BACTERIOPHAGES FOR REDUCING TOXICITY OF BACTERIA**

(75) Inventors: **Ehud Qimron**, Tel Aviv (IL); **Rotem Edgar**, Kfar-Saba (IL); **Nir Friedman**, Nes Ziona (IL)

(73) Assignee: **Ramot at Tel-Aviv University Ltd.**, Tel Aviv (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/477,213**

(22) Filed: **May 22, 2012**

(65) **Prior Publication Data**

US 2013/0315869 A1 Nov. 28, 2013

(51) **Int. Cl.**
C12N 7/00 (2006.01)

(52) **U.S. Cl.**
USPC **424/93.6**; 435/235.1; 435/252.3;
435/264; 435/320.1

(58) **Field of Classification Search**
USPC 424/93.6; 435/235.1, 252.3, 264, 320.1
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,791,932 A	2/1974	Schuurs et al.
3,839,153 A	10/1974	Schuurs et al.
3,850,578 A	11/1974	McConnell
3,850,752 A	11/1974	Schuurs et al.
3,853,987 A	12/1974	Dreyer
3,879,262 A	4/1975	Schuurs et al.
3,901,654 A	8/1975	Gross
3,935,074 A	1/1976	Rubenstein et al.
3,984,553 A	10/1976	Seng et al.
3,996,345 A	12/1976	Ullman et al.
4,034,074 A	7/1977	Miles
4,098,876 A	7/1978	Piasio et al.
4,666,828 A	5/1987	Gusella
4,683,202 A	7/1987	Mullis
4,801,531 A	1/1989	Frossard
4,879,219 A	11/1989	Wands et al.
5,011,771 A	4/1991	Bellet et al.
5,192,659 A	3/1993	Simons

5,272,057 A	12/1993	Smulson et al.
5,281,521 A	1/1994	Trojanowski et al.
5,645,991 A *	7/1997	Berg et al. 435/6.18
2007/0059768 A1 *	3/2007	Gill et al. 435/7.1
2010/0322903 A1 *	12/2010	Collins et al. 424/93.2

FOREIGN PATENT DOCUMENTS

WO	WO 01/12803	*	2/2001	C12N 15/11
WO	WO 2006/075996	*	7/2006	C12N 15/10
WO	WO 2011/084647	*	7/2011	C12N 15/09

OTHER PUBLICATIONS

Westwater et al, Antimicrob. Agents & Chemo. 47(4):1301-1307, 2003.*
 Cheng et al, Appl. Microbiol. Biotechnol. 74:1284-1291, 2007.*
 Agilent Technologies, Uni-ZAP Vector Kit Instruction Manual, 2010.*
 Cheng et al. "Specific gene silencing by artificial trans-encoded small noncoding RNAs in bacteria", Nucleic Acids Research, p. 1-15, May 27, 2009.
 Edgar et al. "Reversing Bacterial Resistance to Antibiotics by Phage-Mediated Delivery of Dominant Sensitive Genes", Applied Environmental Microbiology, 78(3): 744-751, Feb. 2012.
 Hagens et al. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol. 2003; 37(4):318-23.
 Lederberg. "Streptomycin Resistance: A Genetically Recessive Mutation", J. Bacteriol. May 1951 61:549-550.
 Lu et al. "Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy" Proc Natl Acad Sci U S A Mar. 24, 2009;106(12):4629-34.
 Nakashima et al. "Paired Termini Stabilize Antisense RNAs and Enhance Conditional Gene Silencing in *Escherichia coli*", Nucleic Acids Research, 34(20): e138-1-e138-10, Oct. 24, 2006.

* cited by examiner

Primary Examiner — Kevin Hill
(74) *Attorney, Agent, or Firm* — Wiggin and Dana LLP;
Gregory S. Rosenblatt

(57) **ABSTRACT**

A genetically modified bacteriophage is disclosed which comprises:

- (i) an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium; and
- (ii) an exogenous polynucleotide which encodes a selectable marker.

Uses thereof and kits comprising same are also disclosed.

31 Claims, 8 Drawing Sheets

FIG. 1A





FIG. 1B



FIGs. 2A-B





FIG. 3



FIGs. 4A-B




FIG. 5




FIG. 6





FIG. 7



1

**BACTERIOPHAGES FOR REDUCING
TOXICITY OF BACTERIA**FIELD AND BACKGROUND OF THE
INVENTION

The present invention, in some embodiments thereof, relates to a method of reducing toxicity of bacteria and more particularly reducing antibiotic resistance in bacteria.

Bacteria have evolved to overcome a wide range of antibiotics, and resistance mechanisms against most of the conventional antibiotics have been identified in some bacteria. Accelerated development of newer antibiotics is being overrun by the pace of bacterial resistance. In the USA, for example, over 70% of hospital-acquired infections involve bacteria resistant to at least one antibiotic, and in Japan over 50% of the clinical isolates of *Staphylococcus aureus* are multidrug-resistant.

This increasing threat has revived research into phage therapy. For example, a clinical phase I and II control trial was recently completed successfully for the treatment of chronic bacterial ear infections. Nevertheless, although phage therapy has been practiced for several decades in some of the former Soviet Union countries and Poland, there are still many doubts as to its ability to replace antibiotics. Major concerns over the use of phage therapy include neutralization of phages by the spleen/liver and by the immune system, their narrow host range, bacterial resistance to the phage, and lack of sufficient pharmacokinetic and efficacy studies in humans and animals.

A recent study used phages as a genetic tool to increase bacterial susceptibility to antibiotics. That study used phage M13, of the Gram-negative *Escherichia coli*, to genetically target several gene networks, thus rendering the bacteria more sensitive to antibiotics (10). It demonstrated that disrupting the SOS response by M13-mediated gene-targeting renders the bacteria several-fold more sensitive to a variety of antibiotics. It also demonstrated that phage-mediated gene transfer combined with antibiotics increases the survival of mice infected with pathogenic *E. coli*. Overall, the study showed that transferring genes by phage M13 weakens the bacteria, and render them more susceptible to killing by antibiotics. The end result is very similar to conventional phage-therapy practices, in which phages are used to directly kill the pathogen.

Different approaches make use of phages as “disinfectants” of pathogens present on edible foods, plants, and farm animals. In addition to increasing the shelf life of these products, the treatment is intended to prevent occasional outbreaks of disease. The US Food and Drug Administration recently approved the use of an anti-*Listeria* phage cocktail for application on meat and poultry as a preventive measure to against *Listeria* (5). Other phage cocktails have been approved as food additives in Europe, and many are currently being developed by phage biotech companies. These applications demonstrate that phages can be dispersed in the environment and efficiently target pathogens in their surroundings.

Pathogen resistance to antibiotics is a rapidly growing problem, leading to an urgent need for novel antimicrobial agents. Unfortunately, development of new antibiotics faces numerous obstacles, and a method that will resensitize pathogens to approved antibiotics therefore holds key advantages.

Lu and Collins [Proc Natl Acad Sci USA. 2009 Mar. 24; 106 (12):4629-34] teach genetically modified bacteriophage which serve to weaken bacteria such that they are more susceptible to antibiotics.

2

Hagens and Blassi [Lett Appl Microbiol. 2003; 37 (4):318-23] teach genetically modified filamentous phage as bactericidal agents.

Other background art includes U.S. Patent Application No. 20100322903 and Lederberg J., 1951, J Bacteriol 61:549-550 which teaches that wt rpsL is a dominant sensitive allele with regard to streptomycin resistance.

SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided a genetically modified bacteriophage comprising:

- (i) an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium; and
- (ii) an exogenous polynucleotide which encodes a selectable marker.

According to an aspect of some embodiments of the present invention there is provided a kit comprising a compound which is toxic to bacteria and the phage of embodiments of the present invention, wherein the selectable marker renders a bacterium infected by the phage insensitive to the compound.

According to an aspect of some embodiments of the present invention there is provided a genetically modified bacteriophage comprising an exogenous polynucleotide which encodes a polypeptide which reverses resistance of a bacterium to an antibiotic, wherein the polypeptide is selected from the group consisting of 30S ribosomal subunit protein S12, gyrase, RNA Polymerase B Subunit and thymidylate synthase.

According to an aspect of some embodiments of the present invention there is provided an anti-bacterial composition, comprising a carrier and as an active ingredient the bacteriophage of embodiments of the present invention.

According to an aspect of some embodiments of the present invention there is provided a method of preventing a bacterial infection which is resistant to an antibiotic in a subject, the method comprising contacting a solid surface with the anti-bacterial composition described herein, thereby preventing the bacterial infection.

According to an aspect of some embodiments of the present invention there is provided an isolated population of bacterial cells comprising the bacteriophage of embodiments of the present invention.

According to some embodiments of the invention, the selectable marker is not an antibiotic resistance gene.

According to some embodiments of the invention, the agent reverses resistance of the bacterium to an antibiotic.

According to some embodiments of the invention, the resistance is due to a mutated polypeptide of the bacterium selected from the group consisting of 30S ribosomal subunit protein S12, gyrase, RNA Polymerase B Subunit and thymidylate synthase.

According to some embodiments of the invention, the agent is non-toxic to the bacterium.

According to some embodiments of the invention, the agent comprises a polypeptide selected from the group consisting of 30S ribosomal subunit protein S12, gyrase, RNA Polymerase β Subunit and thymidylate synthase.

According to some embodiments of the invention, the agent comprises a 30S ribosomal subunit protein S12.

According to some embodiments of the invention, the 30S ribosomal subunit protein S12 comprises a nucleic acid sequence as set forth in SEQ ID NO: 24.

3

According to some embodiments of the invention, the agent is a polynucleotide agent which down-regulates expression of an antibiotic resistance gene expressed in the bacterium.

According to some embodiments of the invention, the agent is a polynucleotide agent which down-regulates expression of a virulence gene expressed in the bacterium.

According to some embodiments of the invention, the polynucleotide agent is selected from the group consisting of an siRNA, a short hairpin RNA, a ribozyme and a DNase.

According to some embodiments of the invention, the polypeptide is non-toxic to the bacterium.

According to some embodiments of the invention, the polypeptide comprises a 30S ribosomal subunit protein S12.

According to some embodiments of the invention, the 30S ribosomal subunit protein S12 is encoded by a polynucleotide sequence as set forth in SEQ ID NO: 24.

According to some embodiments of the invention, the exogenous polynucleotide further encodes a selectable marker.

According to some embodiments of the invention, the selectable marker comprises a resistance marker to tellurite.

According to some embodiments of the invention, the bacteriophage is a lambda temperate phage.

According to some embodiments of the invention, the antibacterial composition is formulated as a spray, a stick, a paint, a gel, a cream, wash, a wipe, a foam, a soap, an oil, a solution, a lotion, an ointment or a paste.

According to some embodiments of the invention, the method further comprises contacting the solid surface with a compound which is toxic to bacteria.

According to some embodiments of the invention, the method further comprises contacting the solid surface with a compound which is toxic to bacteria.

According to some embodiments of the invention, the exogenous polynucleotide further encodes a selectable marker that renders a bacterium infected by the phage insensitive to the compound.

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

FIGS. 1A-B are maps of plasmid (A) and phage (B). The inserts are drawn to scale, with the relevant genes and genetic elements indicated. CAT—chloramphenicol acetyl transferase, conferring chloramphenicol resistance; Pamp—bla promoter, PA1*—mutated T7-A1 promoter of T7 phage. The

4

promoter could not be cloned without a mutation, and therefore the following 1 bp deletion in the promoter sequence (bolded) was inserted:

T7-A1: AAAAGAGTA

5 TTGACTTAAAGTCTAACCTATAG
GATACTTACAGCCAT (SEQ ID NO: 21,

T7-A1*: AAAAGAGTATTGACTTAAAGTCTAA
CTATAGGATACTTACAGCCAT (SEQ ID NO: 22;

10 rpsLΔ4—encodes a truncated RpsL protein, rpsL-wt—encodes the RpsL protein;

rpsL-sil—encodes an RpsL protein, harboring numerous silent mutations, with only 62% identity to the wt sequence; tehA/tehB—encode proteins which confer tellurite resistance; gyrA-wt—encodes the Gyrase A protein.

15 FIGS. 2A-B are photographs indicating that rpsL encoded by plasmids efficiently sensitizes streptomycin-resistant mutants. Streptomycin-resistant mutants Sm6 and Sm13, transformed with a plasmid encoding wt rpsL, pRpsL-wt (A) or rpsL having multiple silent mutations, pRpsL-sil (B), become more sensitive to streptomycin as compared to mutants transformed with a plasmid encoding a mock gene, pRpsLΔ4. Serial 10-fold dilutions starting at 10⁵ CFU/spot (from top to bottom) of the different mutants were spotted on plates with the indicated streptomycin concentrations. Chloramphenicol was supplemented at 35 μg/ml in all plates to maintain the plasmid. Plates were incubated overnight and photographed using MiniBis Pro (Bio-Imaging Systems). A representative experiment out of three is presented.

20 FIG. 3 is a photograph illustrating that tellurite-resistance genes efficiently replace chloramphenicol acetyl transferase as a selection marker. Streptomycin-resistant mutants transformed with a plasmid encoding wt rpsL as well as a tellurite-resistance gene, pRpsL-sil-tell, become more sensitive to streptomycin as compared to mutants transformed with a plasmid encoding a mock gene, pRpsLΔ4-tell. Serial 10-fold dilutions starting at 10⁵ CFU/spot (from top to bottom) of the different mutants were spotted on plates with the indicated streptomycin concentrations. Tellurite was supplemented at 1.5 μg/ml in all plates to maintain the plasmid. Plates were incubated overnight and photographed using MiniBis Pro (Bio-Imaging Systems). A representative experiment out of three is presented.

25 FIGS. 4A-B are photographs illustrating that rpsL genes introduced by phage λ sensitize a streptomycin-resistant mutant. Phage λ encoding a single copy of either wt rpsL (λ-RpsL-wt-tell) or rpsL-sil (λ-RpsL-sil-tell) sensitizes a streptomycin-resistant mutant, Sm13, compared to phage λ encoding a mock gene (λ-RpsLΔ4-tell) (A). Sensitization is significantly enhanced when the phage carries both copies of rpsL (λ-2xRpsL-tell) (B). Serial 10-fold dilutions starting at 10⁵ CFU/spot (from top to bottom) of the different lysogens were spotted on plates with the indicated streptomycin concentrations. Tellurite was supplemented at 1.5 μg/ml in all plates to maintain the prophage. Plates were incubated overnight and photographed using MiniBis Pro (Bio-Imaging Systems). A representative experiment out of three is presented.

30 FIG. 5 is a photograph illustrating that gyrA introduced by phage λ sensitizes a nalidixic acid-resistant mutant. Phage λ encoding a single copy of wt gyrA (λ-GyrA-tell) sensitizes a nalidixic acid-resistant mutant, Nal2, compared to phage λ encoding a mock gene (λ-Ctrl-tell). Triplicates of the different lysogens, at 10⁴ CFU/spot, were spotted on plates with the indicated streptomycin concentrations. Tellurite was supplemented at 4 μg/ml in all plates. Plates were incubated over-

night and photographed using MiniBis Pro (Bio-Imaging Systems). A representative experiment to out of three is presented.

FIG. 6 is a bar graph illustrating that the *gyrA* gene restores sensitivity to nalidixic acid. An *E. coli* K-12 clone, having S83L substitution in its *gyrA* gene product conferring nalidixic acid (nal) resistance, was transformed with a pUC19 plasmid encoding the wt-*gyrA* or with pUC19 as control. Cells were grown to mid-log phase and serial dilutions were inoculated on plates containing 100 µg/ml amp+50 µg/ml nal (+nal) or 100 µg/ml amp only (-nal). Results show that the wt-*gyrA* gene renders the cells significantly more sensitive to killing by nal compared to the control.

FIG. 7 is a bar graph illustrating the effectiveness of a toxin-antitoxin system for increasing sensitization to antibiotics by decreasing plasmid loss from the bacteria.

DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to a method of reducing toxicity of bacteria and more particularly reducing antibiotic resistance in bacteria.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

According to the World Health Organization, bacteria resistant to antibiotics are one of the three main threats to human health. In the U.S. alone, there are almost 100,000 deaths each year due to infections. Hospitals are places especially critical in regard to the potential impact of bacterial resistance to antibiotics, which are home to people more vulnerable than normal to failing health, and also constitute a meeting point of various infectious bacteria, carried by the patients.

Most acquired bacterial resistance to streptomycin (an aminoglycoside antibiotic) is due to mutations in the *rpsL* (Ribosomal Protein Small subunit) gene. This gene encodes ribosomal protein S12. The present inventors isolated streptomycin resistant strains of *E. coli* K-12 by growth on streptomycin-containing agar plates (50 µg/ml). Resistant mutants arose at a rate of ~1 in 10⁹ CFUs. They isolated 22 mutant strains, 21 of which had mutations in *rpsL*. These specific mutations and their frequencies matched what had been previously observed in clinical isolates, thus were representative of the resistant strains encountered in clinical settings. Concentrating on two of these strains that carried the two point mutations most commonly observed in resistant isolates (one strain having the arginine-86→serine substitution, the other the lysine88→arginine change), the present inventors showed that transformation of resistant strains with plasmids carrying a wild-type (wt) *rpsL* gene rendered the transformants streptomycin sensitive, reducing the MICs of the two strains from 100 µg/ml to 12.5 µg/ml and from 200 µg/ml to 3.125 µg/ml, respectively (see FIGS. 2A-B).

The present inventors propose that the above findings may be adapted so as to enrich for antibiotic-treatable pathogens on hospital surfaces. This enriched, sensitive population might then interfere with the establishment of newly introduced resistant pathogens by overtaking their ecological niche.

Recombination events between the chromosomal resistant *rpsL* and the delivered wt *rpsL* may reduce the efficiency of the construct because it may eventually recombine with an

rpsL copy that does not confer sensitivity on the transformed strains. Efficient homologous recombination requires a high degree of overall identity between two genes, as well as an identical "processing segment" of at least 23-27 bp. In *E. coli*, reducing overall identity from 100% to 90% decreases the frequency of recombination >40-fold. Accordingly, in order to minimize recombination between the introduced wt *rpsL* gene and the resident resistant *rpsL* gene, the present inventors modified the wt *rpsL* gene by introducing silent mutations at the third codon positions. This modified gene, called *rpsL*-sil (silent mutations), had only 62% identity to wt *rpsL* and none of the remaining regions of identity were long enough to serve as a minimum processing segment in recombination. Plasmids with the modified *rpsL*-sil gene were almost as efficient in restoring sensitivity.

Whilst further reducing the present invention to practice, the present inventors engineered λgt11 phage to encode both *rpsL*-sil and tellurite resistance (a gene which allows for resistance to the bacterial toxin, tellurite) and used them to infect one of their streptomycin resistant strains at 32° C. They selected lysogens on agar plates supplemented with tellurite. The streptomycin MIC for the lysogens was reduced from 200 µg/ml to 50 µg/ml (FIG. 4A). To further enhance sensitivity, the present inventors engineered a λgt11 phage that encoded two, one wt *rpsL* and one *rpsL*-sil. Lysogenization with this phage brought the streptomycin MIC down to 1.56 µg/ml (FIG. 4B), i.e., to the sensitivity observed in wt *E. coli* K-12, thus proving that engineered phages can efficiently and effectively restore streptomycin sensitivity to a resistant strain.

The present approach differs from conventional phage therapy in the sense that it does not use phages to kill the pathogens directly. Consequently, there is no selection against the used phage, but rather selection for pathogens harboring the phage because it contains tellurite resistance. Moreover, the approach avoids the use of phages inside the patient's body, thus overcoming toxicity issues and other drawbacks of phage therapy, such as phage neutralization by the spleen and the immune system.

Thus, according to one aspect of the present invention, there is provided a genetically modified bacteriophage comprising an exogenous polynucleotide which encodes an agent which reduces the toxicity of a bacterium.

As used herein, the term "bacteriophage" (also referred to herein as phage) refers to a virus of a bacterium. The bacteriophage may constitute a single or double-stranded DNA or RNA virus. The present inventors contemplate use of temperate, lytic or temperature-sensitive temperate bacteriophage, where at a particular temperature (e.g. at 36° C. or below) the phage favors lysogeny, whereas higher temperatures induce lytic production of the phage. An example of this type of phage is the λgt11 phage. Other λ phages having their *cl* gene changed to the *cl*857 allele are also contemplated since they will exhibit similar growth pattern. Preferably, the phage is selected such that it allows stable insertion of at least 1 kb of foreign DNA and more preferably at least 5 kb of foreign DNA.

According to another embodiment, the phage comprises deletion mutants with minimal genes and is capable of efficient lysogenization.

Other examples of phage contemplated by the present invention include those disclosed in U.S. Patent Application No. 20100322903, incorporated herein by reference.

Identification of phages capable of infecting additional bacteria is within the scope of one skilled in the art.

The phages used for infecting the bacteria may be capable of integrating into a gram positive or gram negative bacteria.

The term “Gram-positive bacteria” as used herein refers to bacteria characterized by having as part of their cell wall structure peptidoglycan as well as polysaccharides and/or teichoic acids and are characterized by their blue-violet color reaction in the Gram-staining procedure.

Representative Gram-positive bacteria include: *Actinomyces* spp., *Bacillus anthracis*, *Bifidobacterium* spp., *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium* spp., *Clostridium tetani*, *Corynebacterium diphtheriae*, *Corynebacterium jeikeium*, *Enterococcus faecalis*, *Enterococcus faecium*, *Erysipelothrix rhusiopathiae*, *Eubacterium* spp., *Gardnerella vaginalis*, *Gemella morbillorum*, *Leuconostoc* spp., *Mycobacterium abscessus*, *Mycobacterium avium* complex, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium haemophilium*, *Mycobacterium kansasii*, *Mycobacterium leprae*, *Mycobacterium marinum*, *Mycobacterium scrofulaceum*, *Mycobacterium smegmatis*, *Mycobacterium terrae*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Nocardia* spp., *Peptococcus niger*, *Peptostreptococcus* spp., *Propionibacterium* spp., *Staphylococcus aureus*, *Staphylococcus auricularis*, *Staphylococcus capitis*, *Staphylococcus cohnii*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus lugdunensis*, *Staphylococcus saccharolyticus*, *Staphylococcus saprophyticus*, *Staphylococcus schleiferi*, *Staphylococcus similans*, *Staphylococcus warneri*, *Staphylococcus xylosus*, *Streptococcus agalactiae* (group B streptococcus), *Streptococcus anginosus*, *Streptococcus bovis*, *Streptococcus canis*, *Streptococcus equi*, *Streptococcus milleri*, *Streptococcus mitior*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes* (group A streptococcus), *Streptococcus salivarius*, *Streptococcus sanguis*.

The term “Gram-negative bacteria” as used herein refer to bacteria characterized by the presence of a double membrane surrounding each bacterial cell. Representative Gram-negative bacteria include *Acinetobacter calcoaceticus*, *Actinobacillus actinomycetemcomitans*, *Aeromonas hydrophila*, *Alcaligenes xylosoxidans*, *Bacteroides*, *Bacteroides fragilis*, *Bartonella bacilliformis*, *Bordetella* spp., *Borrelia burgdorferi*, *Branhamella catarrhalis*, *Brucella* spp., *Campylobacter* spp., *Chlamydia pneumoniae*, *Chlamydia psittaci*, *Chlamydia trachomatis*, *Chromobacterium violaceum*, *Citrobacter* spp., *Eikenella corrodens*, *Enterobacter aerogenes*, *Escherichia coli*, *Flavobacterium meningosepticum*, *Fusobacterium* spp., to *Haemophilus influenzae*, *Haemophilus* spp., *Helicobacter pylori*, *Klebsiella* spp., *Legionella* spp., *Leptospira* spp., *Moraxella catarrhalis*, *Morganella morganii*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Plesiomonas shigelloides*, *Prevotella* spp., *Proteus* spp., *Providencia rettgeri*, *Pseudomonas aeruginosa*, *Pseudomonas* spp., *Rickettsia prowazekii*, *Rickettsia rickettsii*, *Rochalimaea* spp., *Salmonella* spp., *Salmonella typhi*, *Serratia marcescens*, *Shigella* spp., *Treponema carateum*, *Treponema pallidum*, *Treponema pallidum endemicum*, *Treponema pertenue*, *Veillonella* spp., *Vibrio cholerae*, *Vibrio vulnificus*, *Yersinia enterocolitica*, *Yersinia pestis*.

Specific examples of *E. coli* include, but are not limited to enteroaggregative (EAEC), enterohemorrhagic (EHEC), enteroinvasive (EIEC), enteropathogenic (EPEC), enterotoxigenic (ETEC) and diffuse adherent (DAEC) *E. coli*.

An exemplary *E. coli* serotype contemplated by the present invention is O157:H7.

Modification of the bacteriophage of this aspect of embodiments of the present invention may be effected using any

method known in the art, including standard cloning techniques, artificial selection for host-range mutants, and homologous recombination.

Agents which reduce the toxicity of a bacteria include agents which reduce the ability of the bacteria to bring about infection in mammalian cells. The agents may be capable of reducing the virulence of a bacteria or may be capable of reversing resistance to an antibiotic agent. According to this embodiment, the agent does not directly affect the survival of the bacteria.

Agents which may be expressed in the bacteriophage include both polypeptide and polynucleotide agents (an siRNA, a short hairpin RNA, a ribozyme and a DNase). Such agents are further described herein below.

In order to express an exogenous polypeptide or polynucleotide agent in a bacteriophage, a polynucleotide encoding the polypeptide (or the polynucleotide agent) is inserted into the phage DNA under control of a promoter which is active in the bacteria.

Examples of phage promoters which may be used in the context of the present invention are disclosed in U.S. Patent Application No. 20100322903, incorporated herein by reference.

According to one embodiment, the bacteriophages are used to reverse the antibiotic resistance bacteria expressing an antibiotic resistant gene that is a dominant sensitive antibiotic resistant gene.

Such genes include the *rpsL* gene (Genebank NC_000913 nt 3472200-3472574—SEQ ID NO: 23) encoding the 30S ribosomal subunit protein S12, mutations of which are known to cause resistance to streptomycin; the *gyrA* gene encoding the gyrase protein (Genebank NC_000913 nt 2334815.2337442—SEQ ID NO: 26), mutations of which are known to cause resistance to quinolone antibiotics such as nalidixic acid, the *rpoB* gene (SEQ ID NO: 28) that encodes the RNA Polymerase β Subunit, mutations of which are known to cause resistance to rifamycin and the *thyA* gene (Genebank NC_000913 nt 2962383-2963177—SEQ ID NO: 30) that encodes thymidylate synthase, mutations of which are known to cause resistance to trimethoprim.

The amino acid sequence of the wild-type 30S ribosomal subunit protein S12 is set forth in SEQ ID NO: 25.

The amino acid sequence of the wild-type gyrase protein is set forth in SEQ ID NO: 27.

The amino acid sequence of the wild-type RNA Polymerase β Subunit is set forth in SEQ ID NO: 29.

The amino acid sequence of the wild-type thymidylate synthase is set forth in SEQ ID NO: 31.

Accordingly, the present inventors contemplate modifying bacteriophage by inserting polynucleotide sequences encoding SEQ ID NO: 25, 27, 29 and/or 31 therein.

The present invention further contemplates modifying the polynucleotide sequences in order to minimize recombination between the introduced wildtype genes and the resident resistant gene which would reduce the effectiveness of the strategy. Efficient homologous recombination requires a high degree of overall identity between the two genes, as well as an identical “processing segment” of at least 23-27 bp. In *E. coli*, reducing overall identity from 100% to 90% decreases the frequency of recombination >40-fold. Thus, the present invention contemplates modifying the wt *rpsL* gene by introducing silent mutations (e.g. at the third codon positions) so as not to affect the amino acid sequence of the encoded proteins.

The modified genes may be about 90% identical, 80% identical, 70% identical, 60% identical or even 50% identical to the wildtype genes. Preferably, none of the remaining

regions of identity are long enough to serve as a minimum processing segment in recombination.

An exemplary polynucleotide sequence encoding wild-type 30S ribosomal subunit protein S12, modified so as to prevent homologous recombination is set forth in SEQ ID NO: 24.

It will be appreciated that the bacteriophages of this aspect of the present invention may also be modified to express more than one of the above disclosed dominant-sensitive genes. Additionally, or alternatively, the bacteriophages of this aspect of the present invention may be modified to express more than one copy of any one of the above mentioned wild-type dominant-sensitive genes.

As mentioned, additionally, or alternatively, the bacteriophages of this aspect of the present invention may be genetically modified to express polynucleotide agents (RNA silencing agents) capable of downregulating expression of genes responsible for antibiotic resistance or bacterial virulence.

The phrase “antibiotic resistance genes” as used herein refers to genes that confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, actively exports it, or by being a mutant form of the antibiotic’s target so that it can ignore it.

Example of antibiotic resistance genes may be found on the ARDB—Antibiotic Resistance Genes Database. Particular examples of antibiotic resistance genes include, but are not limited to extended-spectrum beta lactamase (ESBL) genes, methicillin resistance gene, CTX-M-15; ndm-1,2,5,6 or a vancomycin resistance gene.

As mentioned, as well as targeting antibiotic resistance genes, the siRNAs of this aspect of the present invention may be targeted against virulence genes. Preferably, the RNA silencing agents of this aspect of the present invention do not target a gene that affects the propagation and/or respiration of the bacteria (i.e. essential genes).

The phrase “virulence gene” as used herein refers to a nucleic acid sequence of a microorganism, the presence and/or expression of which correlates with the pathogenicity of the microorganism. In the case of bacteria, such virulence genes may in an embodiment comprise chromosomal genes (i.e. derived from a bacterial chromosome), or in a further embodiment comprise a non-chromosomal gene (i.e. derived from a bacterial non-chromosomal nucleic acid source, such as a plasmid). In the case of *E. coli*, examples of virulence genes and classes of polypeptides encoded by such genes are described below. Virulence genes for a variety of pathogenic microorganisms are known in the art.

Examples of virulence genes include, but are not limited to genes encoding toxins (e.g. Shiga toxin and cholera toxin), hemolysins, fimbrial and afimbrial adhesins, cytotoxic factors, microcins and colicins and also those identified in Sun et al., *Nature Medicine*, 2000; 6 (11): 1269-1273.

According to one embodiment of the invention, the bacterial virulence gene may be selected from the group consisting of actA (example is given in genebank accession no: NC_003210.1), Tem (example is given in genebank accession no: NC_009980), Shy (example is given in genebank accession no: NC_009648), oxa-1 (example is given in genebank accession no: NW_139440), oxa-7 (example is given in genebank accession no: X75562), pse-4 (example is given in genebank accession no: J05162), ctx-m (example is given in genebank accession no: NC_010870), ant(3'')-Ia (aadA1) (example is given in genebank accession no: DQ489717), ant(2'')-Ia (aadB)b (example is given in genebank accession no: DQ176450), aac(3)-IIa (aacC2) (ex-

ample is given in genebank accession no: NC_010886), aac(3)-IV (example is given in genebank accession no: DQ241380), aph(3')-Ia (aphA1) (example is given in genebank accession no: NC_007682), aph(3')-IIa (aphA2) (example is given in genebank accession no: NC_010170), tet(A) (example is given in genebank accession no: NC_005327), tet(B) (example is given in genebank accession no: FJ411076), tet(C) (example is given in genebank accession no: NC_010558), tet(D) (example is given in genebank accession no: NC_010558), tet(E) (example is given in genebank accession no: M34933), tet(Y) (example is given in genebank accession no: AB089608), catI (example is given in genebank accession no: NC_005773), catII (NC_010119), catIII (example is given in genebank accession no: X07848), floR (example is given in genebank accession no: NC_009140), dhfrI (example is given in genebank accession no: NC_002525), dhfrV (example is given in genebank accession no: NC_010488), dhfrVII (example is given in genebank accession no: DQ388126), dhfrIX (example is given in genebank accession no: NC_010410), dhfrXIII (example is given in genebank accession no: NC_000962), dhfrXV (example is given in genebank accession no: Z83311), suII (example is given in genebank accession no: NC_000913), suIII (example is given in genebank accession no: NC_000913), integron class 1 3'-CS (example is given in genebank accession no: AJ867812), vat (example is given in genebank accession no: NC_011742), vatC (example is given in genebank accession no: AF015628), vatD (example is given in genebank accession no: AF368302), vatE (example is given in genebank accession no: NC_004566), vga (example is given in genebank accession no: AF117259), vgb (example is given in genebank accession no: AF117258), and vgbB (example is given in genebank accession no: AF015628).

As used herein, the phrase “RNA silencing” refers to a group of regulatory mechanisms [e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co-suppression, and translational repression] mediated by RNA molecules which result in the inhibition or “silencing” of the expression of a corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.

As used herein, the term “RNA silencing agent” refers to an RNA which is capable of specifically inhibiting or “silencing” the expression of a target gene. In certain embodiments, the RNA silencing agent is capable of preventing complete processing (e.g. the full translation and/or expression) of an mRNA molecule through a post-transcriptional silencing mechanism. RNA silencing agents include noncoding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated. Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs. In one embodiment, the RNA silencing agent is capable of inducing RNA interference. In another embodiment, the RNA silencing agent is capable of mediating translational repression.

According to an embodiment of the invention, the RNA silencing agent is specific to the target RNA and does not cross inhibit or silence a gene or a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% global homology to the target gene.

RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated

by short interfering RNAs (siRNAs). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla. Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA.

Accordingly, some embodiments of the invention contemplate use of dsRNA to downregulate protein expression from mRNA.

According to one embodiment, the dsRNA is greater than 30 bp. (siRNAs).

According to another embodiment, the dsRNA is an siRNA.

The term “siRNA” refers to small inhibitory RNA duplexes (generally between 18-30 basepairs) that induce the RNA interference (RNAi) pathway.

The strands of a double-stranded interfering RNA (e.g., an siRNA) may be connected to form a hairpin or stem-loop structure (e.g., an shRNA). Thus, as mentioned the RNA silencing agent of some embodiments of the invention may also be a short hairpin RNA (shRNA).

The term “shRNA”, as used herein, refers to an RNA agent having a stem-loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region. The number of nucleotides in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop. Examples of oligonucleotide sequences that can be used to form the loop include 5'-UUCAAGAGA-3' (Brummelkamp, T. R. et al. (2002) *Science* 296: 550) and 5'-UUUGUGUAG-3' (Castanotto, D. et al. (2002) *RNA* 8:1454). It will be recognized by one of skill in the art that the resulting single chain oligonucleotide forms a stem-loop or hairpin structure comprising a double-stranded region capable of interacting with the RNAi machinery.

Methods of designing siRNA agents for downregulating gene expression in bacteria are provided in Nakashima et al *Nucleic Acids Research*, 2006, Vol. 34, No. 20 and Cheng et al., *Nucleic Acids Research*, 2009, 1-15, the contents of which are incorporated herein by reference.

Another agent capable of downregulating expression in bacteria is a DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of the mutated antibiotic resistance gene. DNAzymes are single-stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R. R. and Joyce, G. *Chemistry and Biology* 1995; 2:655; Santoro, S. W. & Joyce, G. F. *Proc. Natl. Acad. Sci. USA* 1997; 94: 4262) A general model (the “10-23” model) for the DNAzyme has been proposed. “10-23” DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (San-

toro, S. W. & Joyce, G. F. *Proc. Natl. Acad. Sci. USA* 199; for rev of DNAzymes see Khachigian, L M [*Curr Opin Mol Ther* 4:119-21 (2002)].

Another agent capable of downregulating expression in bacteria is a ribozyme molecule capable of specifically cleaving its mRNA transcript. Ribozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., *Curr Opin Biotechnol.* 9:486-96 (1998)]. The possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications. In the therapeutics area, ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., *Clin Diagn Virol.* 10:163-71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials. ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway. Ribozyme Pharmaceuticals, Inc., as well as other firms have demonstrated the importance of anti-angiogenesis therapeutics in animal models. HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated—WEB home page).

Preferably, the polynucleotides used to modify the bacteriophages of this aspect of the present invention encode a selectable marker so that positive transformants may be selected.

As used herein, the phrase “a selectable marker” refers to a trait that protects the organism from a selective agent that would normally kill it or prevent its growth.

Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

According to a particular embodiment, the selectable marker is one that confers resistance to a toxic (bactericidal) compound.

For the purposes of this invention, an agent may be considered to be an antibiotic if it is at least 5 fold (and more preferably 10) fold more lethal to bacteria than to mammalian cells whereas a toxic compound has is less than 10 fold and more preferably less than 5 fold more lethal to bacteria than to mammalian cells.

According to another embodiment, the selectable marker is not an antibiotic resistance gene.

According to a specific embodiment, the polynucleotide encodes the tehAB operon (SEQ ID NO: 32) which confers resistance against potassium-tellurite (K_2TeO_3). Tellurite is a toxic compound to bacteria as it forms long lived sulfur complexes, thus disrupting the thiol balance within the cells. The tehAB genes increase the minimal inhibitory concentration (MIC) of tellurite against *E. coli* 50-100 fold upon expression from an active promoter, although they do not confer resistance to the *E. coli* when present in the chromosome under their endogenous promoter. The observed MIC of

E. coli either having or lacking the chromosomal *tehAB* genes is 2 µg/ml compared to a MIC of 128 µg/ml in cells harboring an extrachromosomal *tehAB* with an active promoter.

Additional toxins that may be used as selectable markers include chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

Additional methods to counteract antibiotic pressure and to maintain the stability of the plasmid conferring sensitivity to antibiotics include use of a toxin-antitoxin system. In such systems, a long lived toxin and a short lived antitoxin are encoded. The antitoxin, which is constantly produced, eliminates the toxin activity as long as the encoding DNA is present in the cell. However, if the DNA is lost, the long lived toxin exerts its effect resulting in cell death as no antitoxin is encoded to counteract it. Genetic linkage of such a system to the DNA sensitizing cassette should maintain the DNA construct despite antibiotic treatment. Pathogens that lose the DNA construct are killed by the toxin because they lose the antitoxin encoding DNA. As illustrated in FIG. 7, sensitization to antibiotics increased more than 100 fold upon linking one such system, the *hok/sok*, to streptomycin-sensitizing genes.

Other toxin antitoxin systems that may be used in accordance with the present invention include *phd/doc*; *mazE/mazF*; *RNAII*; *T is/B*; *LdrD/RdID*; *FlmA/FlmB*; *Ibs/Sib*; *TxpA/RatA*; *SymE/SymR*; *XCV2162/ptaRNA1*; *CcdB/CcdA*; *ParE/ParD*; *yafO/yafN*; *HicB/HicA*; *Kid/Kis*.

To further overcome possible loss of the drug-sensitizing genes the toxin antitoxin system may be designed such that their presence will be required for acquisition of tellurite resistance, and therefore their expression will be advantageous to the pathogens.

For example, the sensitizing genes may be positioned before the promoter-less tellurite-resistance genes. Tellurite resistance will be thus dependent on expression of the sensitizing genes. In addition, the DNA construct transferred with tellurite resistance may be flanked by genetic markers whose role is to ensure that tellurite resistance is conferred only when the complete drug-sensitizing cassette is present in the bacterium. Such markers may encode the short ~100 bp amber and ochre suppressor tRNA genes. In this case, the tellurite resistance genes typically should harbor both amber and ochre stop codons. The amber and ochre tRNA genes will act as suppressors, allowing translation of the tellurite resistance gene despite the presence of the stop codons. In the event that only a portion of the cassette is transferred, the tellurite resistance will not be expressed due to absence of one or two of the tRNA suppressors and/or the promoter.

The present inventors contemplate use of the above described bacteriophages to infect bacterial populations on solid surfaces, rendering antibiotic insensitive bacteria residing thereon to become sensitive to antibiotic.

Cocktails of different bacteriophages may be applied to solid surface, each bacteriophage having a different host specificity, each carrying genes for tellurite (or other similar toxic compound) resistance as well as genes that confer dominant sensitivity to a variety of antibiotics. It will be appreciated that the bacteriophages are not bactericidal to their hosts since the bacteriophages are not modified to express agents that are toxic to bacteria. Accordingly, in order to enrich for antibiotic-sensitive populations, the present invention further contemplates contacting the solid surface with the bactericidal protein product of the selectable marker encoded in the phage. Thus, for example, in the case where the genetically modified bacteriophage encodes the *tehAB* operon, the solid surface is also contacted with tellurite.

The enriched, antibiotic-sensitive populations might then interfere with the establishment of newly introduced resistant pathogens by overtaking their ecological niche. The present approach differs from conventional phage therapy in the sense that it does not use phages to kill the pathogens directly. Consequently, there is no selection against the used phage, but rather selection for pathogens harboring the phage because it contains tellurite resistance. Moreover, the approach avoids the use of phages inside the patient's body, thus overcoming toxicity issues and other drawbacks of phage therapy, such as phage neutralization by the spleen and the immune system.

As used herein the term "contacting" refers to the positioning of the bacteriophages (and optionally, the toxic compound) of the present invention such that they are in direct or indirect contact with the bacterial cells. Thus, the present invention contemplates both applying the bacteriophages (and optionally the toxic compound) of the present invention to a desirable surface and/or directly to the bacterial cells.

Contacting surfaces with the bacteriophages (and optionally the toxic compound) can be effected using any method known in the art including spraying, spreading, wetting, immersing, dipping, painting, ultrasonic welding, welding, bonding or adhering.

The present invention envisages contacting a wide variety of surfaces with the bacteriophages (and optionally, the toxic compound) of the present invention including fabrics, fibers, foams, films, concretes, masonries, glass, metals, plastics, polymers, and like.

According to a particular embodiment, the bacteriophages (and optionally, the toxic compound) are contacted with surfaces present in a hospital, hospice, old age home, or other such care facility.

Other surfaces related to health include the inner and outer aspects of those articles involved in water purification, water storage and water delivery, and those articles involved in food processing. Thus the present invention envisions coating a solid surface in a food or beverage factory.

Surfaces related to health can also include the inner and outer aspects of those household articles involved in providing for nutrition, sanitation or disease prevention. Thus, the bacteriophages (and optionally toxic compound) of the present invention may also be used for disinfecting toilet bowls etc.

According to one embodiment, the bacteriophages and toxic compound are applied every 12 hours, daily, 6 times a week, 5 times a week, four times a week, three times a week, twice a week or even once a week to the solid surface.

The bacteriophages and toxic compound may be applied concurrently, or one following the other. Alternatively, the bacteriophages may be applied on consecutive days.

Once novel genetically modified bacteriophages are generated they may be tested against specific pathogens such as *M. tuberculosis* and Extended Spectrum Beta Lactamase (ESBL) *Klebsiella pneumoniae*. For safety reasons, lack of toxins in each new lysogenizing phage should be tested. Mice cages may be used to simulate hospital rooms, and mice to simulate patients. In one exemplary test, all cages may be spread with resistant pathogens. The efficiency of the engineered phages to enrich for to drug-sensitive pathogen population in cages may be assessed by spraying phages followed by tellurite for several days. Mice may then be put in these cages or untreated cages, and those developing bacterial disease will be treated with antibiotics. It is expected that mice in the phage-treated cages will be cured by the antibiotics whereas mice in the control cages will succumb to the bacterial disease.

It is expected that during the life of a patent maturing from this application many relevant selectable markers and corresponding toxic compounds will be developed and the scope of those terms are intended to include all such new technologies a priori.

As used herein the term "about" refers to $\pm 10\%$.

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".

The term "consisting of" means "including and limited to".

The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases to "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

As used herein, the term "treating" includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A Laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells—A Manual of Basic Technique" by Freshney, Wiley-Liss, N.Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, Calif. (1990); Marshak et al., "Strategies for Protein Purification and Characterization—A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Materials and Methods

Bacterial Strains.

A partial list of bacterial strains used in this study are listed in Table 1.

17

TABLE 1

Source	Description	<i>E. coli</i> strain
Lab collection	Wild type	K-12
Stratagene	e14-(McrA-) Δ(lac)U169 supE supF hsdR metB trpR tonA21 proC::Tn5 (Kan ^r) [pMC9 Amp ^r Tet ^r]	Y1088
Lab collection	supF58, supE44, mel-1, F ⁺	Ymel

Table 2 recites the *E. coli* K-12 streptomycin-resistant mutants, Sm1-22, isolated on 50 μg/ml streptomycin. Substitutions in the RpsL protein are indicated, as well as the MIC to streptomycin.

TABLE 2

MIC (mg/ml)	Substitution in RpsL	Streptomycin-resistant mutant
≥50	P42S	Sm1
800	K43L	Sm2
≥50	K43N	Sm3
≥50	R54S	Sm4
≥50	R86S	Sm5
100	R86S	Sm6
≥50	R86S	Sm7
≥50	R86S	Sm8
≥50	R86S	Sm9
≥50	R86S	Sm10
≥50	K88E	Sm11
400	K88R	Sm12
400	K88R	Sm13
400	K88R	Sm14
400	K88R	Sm15
400	K88R	Sm16
400	K88R	Sm17
400	K88R	Sm18
400	K88R	Sm19
400	K88R	Sm20
400	K88R	Sm21
≥50	none	Sm22

Table 3 recites *E. coli* K-12 nalidixic acid-resistant mutants, Nal1-8, isolated on 50 μg/ml nalidixic acid. Substitutions in the GyrA protein are indicated, as well as the MIC to nalidixic acid.

TABLE 3

MIC (μg/ml)	Substitution in GyrA	Nalidixic acid-resistant mutant
≥50	S83L	Nal1
≥50	S83L	Nal2
≥50	S83L	Nal3
128	D87G	Nal4
128	D87G	Nal5
128	D87G	Nal6
128	D87G	Nal7
128	D87G	Nal8

Oligonucleotides used in this study are listed in 4.

TABLE 4

Sequence	Primer
CAATAACCCTGATAAATGCTTCAATAATATTGAAA AAGGAAGAGTACTAGTATGCAGAGCGATAAAGTGC TCAA SEQ ID NO: 1	N1

18

TABLE 4-continued

Sequence	Primer
AAGTTTTAAATCAATCTAAAGTATATATGAGTAAA CTTGGTCTGACAGCTCGAGTCATTTTTTACGTGCC AGCA SEQ ID NO: 2	N2
TCGTTTTACAACGTCGTGGATCCTTACCAATGCTT AATCAGTGAGGCTCGGATTATCAAAAAGGATCTTC ACCTAGATCC SEQ ID NO: 3	RE22
ACTTAAGCTTAAAAGAGTATTGACTTAAAGTCTAA CTATAGGATACTTACAGCCATAGGAGGACAGCTAT GGCAACAGTTAACCAGCT SEQ ID NO: 4	217Fa
TTCGGAATTCTTAAGCCTTAGGACGCTTCA SEQ ID NO: 5	217R
GCTAGAATTCGGCGACGGCTTCAAATTTAG SEQ ID NO: 6	220Fa
CATATGTTATTC TTCTTCTGGC TCGTC SEQ ID NO: 7	220Ra
ACTTTCTAGAAGGAAACAGCTATGACCATG SEQ ID NO: 8	223R
TAACGGATCCTTACCAATGCTTAATCAGTG SEQ ID NO: 9	223F
TAACGGATCCACGACGTTGTAAAACGACGG SEQ ID NO: 10	224F
ACTTTCTAGAAGGTGAAGATCCTTTTTGAT SEQ ID NO: 11	224R
ACGCCAATTGGTATGTTGTGTGGAATTGTG SEQ ID NO: 12	231R
CGTTCAATTGGTTAAGGGATTTTGGTCATG SEQ ID NO: 13	231F
CAGACATGTATACCCCGTAC SEQ ID NO: 14	232F
TACGCCATGGCCGAGTGGC SEQ ID NO: 15	232R
GTGTGAAATTGTTATCCGCT SEQ ID NO: 16	233F
ACTGACTAGTACTCTTCTTTTTCAATATTATTG SEQ ID NO: 17	234Fb
CTGTCAGACCAAGTTTACTCCTGTCAGACCAAGTT TACTC SEQ ID NO: 18	234R
ACTGACTAGTATGGAGAAAAAATCACTGG SEQ ID NO: 19	235Fb
TTCACTCGAGTTACGCCCCGCTGCCACTC SEQ ID NO: 20	235R

Isolation of Resistant Mutants.

Over twenty different overnight cultures of a total of ~10¹¹ *E. coli* K-12 cells were inoculated on Luria-Bertani (LB)-agar plates containing 50 μg/ml streptomycin or 50 μg/ml nalidixic acid. Resistant mutants emerged, in both cases, at a median frequency of ~1 in 10⁹ CFU, and were picked from different cultures, to reduce the occurrence of sibling mutants. These bacteria were streaked on an agar plate containing the appropriate antibiotic. The rpsL or gyrA genes of resistant mutants emerging on the plate were PCR-amplified followed by DNA sequencing.

Plasmid Construction.

Plasmids were constructed using standard molecular to biology techniques. DNA segments were amplified by PCR. Standard digestion of the PCR products and vector by restriction enzymes was carried out according to the manufacturer's instructions.

rpsL-wt, rpsL-sil, and gyrA Cloning.

The rpsL gene with multiple silent mutations was designed and supplied by IDT. An EcoRI-HindIII fragment containing a mutated A1 T7 promoter, consensus Shine-Dalgarno (SD) and the rpsL-sil open reading frame (ORF) was cloned into a pUC19 plasmid (HindIII-EcoRI). Wild type rpsL was amplified from the *E. coli* chromosome using primers 217Fa/217R containing the same mutated A1 T7 promoter and SD, and cloned into a pUC19 plasmid (HindIII-EcoRI). For construction of p2XRpsL-tell, the rpsL-wt and rpsL-Sil were first cloned on the same plasmid. These genes were amplified with primers 223F/R and 224F/R, respectively, and cloned in pUC19. Primers 220Fa/Ra were used for amplification of the gyrA gene containing its endogenous promoter and its known transcription repression and activation sites. The resulting PCR product was cloned as an EcoRI-NdeI fragment.

Replacement of the Ampicillin Resistance Gene and Construction of RpsL Mock Gene.

In order to replace the antibiotic marker of pUC19, encoding the bla gene, the cat gene was amplified from plasmid pACYC184 using primers 235Fb/R and digested with SpeI-XhoI. The pUC plasmids described above were PCR amplified using primers 234Fb/234R, digested with SpeI-XhoI and ligated to the cm fragment, resulting in plasmids pRpsl-wt, pRpsl-sil, p2xRpsL and pGyrA. To construct plasmid pRpsLΔ4, pRpsL-wt was digested with SphI, blunt ended using Quick Blunting Kit (NEB) and religated. This procedure deleted 4 base pairs (bp) resulting in a frame shift after amino acid 26 of the RpsL protein.

Phages.

Genetic engineering of the different phages was carried out using λgt11/EcoRI/Gigapack™ III Gold Cloning Kit (Stratagene) according to the manufacturer's protocols. Briefly, EcoRI-digested arms of phage λgt11 were used to construct the lysogenizing phage carrying the different DNA inserts, encoding a chloramphenicol-resistance gene. DNA inserts were PCR amplified from plasmids pRpsL-wt, pRpsL-sil, pRpsLΔ4 (FIG. 1A) using primers 231F/R (Table 4), and digested with MfeI restriction enzyme, which produces ends that are compatible with EcoRI. Ligation was carried out using T4 DNA ligase (New England Biolabs). The ligated products were transformed into *E. coli* strain Y1088, which supports λgt11 growth. Generated plaques were propagated in *E. coli* Y1088 or *E. coli* ymel, which were then used to lysogenize the hosts. In several cases, phages were further manipulated in a host which lacks supE, a suppressor gene necessary for phage growth. In such cases, the phage was transferred by P1-mediated transduction to a permissive host and propagated there. Phages carrying tellurite resistance were constructed by homologous recombination-based genetic engineering of the tellurite-resistance marker instead of the chloramphenicol-resistance gene. The tellurite-resistance genes tehAB were amplified from the *E. coli* chromosome using primers N1/N2 (Table 4) for λ-RpsLΔ4-tell, λ-RpsL-wt-tell, λ-RpsL-sil-tell, λ-Ctrl-tell, and λ-GyrA-tell (FIG. 1B). Primers RE22/N2 (Table 4) were used for construction of λ-2λxRpsL-tell. The obtained PCR products were used for homologous recombination-based genetic engineering as described below.

Homologous Recombination-Based Genetic Engineering.

Homologous recombination using short-homology flanking ends was performed as known in the art (13). Briefly, an overnight culture of lysogens carrying different DNA inserts encoding the chloramphenicol-resistance gene was diluted 75-fold in 25 ml LB medium with appropriate antibiotics and grown at 32° C. in a shaking water bath to an OD₆₀₀ of 0.6. Then, half of the culture was heat-induced for recombination function of the prophage at 42° C. for exactly 4 minutes in a shaking water bath. The remaining culture was left at 32° C. as the uninduced control. The induced and uninduced samples were immediately cooled on ice slurry and then pelleted at 3600 g at 0° C. for 10 minutes. The pellet was washed twice in ice-cold ddH₂O, then resuspended in 200 μl ice-cold ddH₂O and kept on ice until electroporation with ~500 ng of a gel-purified PCR product encoding the tellurite-resistance genes. A 25-μl aliquot of electrocompetent cells was used for each electroporation in a 0.1-cm cuvette at 25 μF, 1.75 kV and 200Ω. After electroporation, the bacteria were recovered in 1 ml LB for 1 hour in a 32° C. shaking water bath and inoculated on selection plates containing 1 to 4 μg/ml tellurite. The DNA insertion into the resulting phages, λ-RpsLΔ4-tell, λ-RpsL-wt-tell, λ-RpsL-sil-tell, λ-Ctrl-tell, λ-GyrA-tell, and λ-2xRpsL-tell, was confirmed by PCR using primer 233F along with 232F or 232R.

Lysogenization.

Overnight culture of the resistant mutants was diluted 1:100 in LB with the appropriate antibiotics, 10 mM MgSO₄ and 0.2% (W/V) maltose. When the culture reached an OD₆₀₀ of 0.6-0.8, 100 μl was mixed with 10 μl phage λ, carrying a resistance gene, in a 1.5-ml tube and incubated at room temperature for 20 minutes. Cells were inoculated on appropriate selection plates and incubated overnight at 32° C. Lysogens emerged on selection plates to which the phage carried a resistance gene. Lysogenization was validated by plating the lysogens at 42° C.: lysogens cannot grow at this temperature because the prophage is induced to its lytic cycle.

Transductions.

Transductions were used to transfer antibiotic-resistance markers or complete λ, phages between strains (in cases where the strain did not carry suppressor genes required for λ growth). P1 lysate was prepared as follows: overnight cultures of donor strain were diluted 1:100 in 2.5 ml LB+5 mM CaCl₂+0.2% (W/V) glucose. After 1 h shaking at 37° C. (or 32° C. for lysogens), 10⁷-10⁸ PFU of phage P1 was added. Cultures were aerated for 1 to 3 h, until lysis occurred. The obtained P1 lysate was used in transduction where 100 μl fresh overnight culture was mixed with 1.25 μl of 1 M CaCl₂ and 0 to 100 μl P1 phage lysate. After incubation for 30 min at 30° C. without shaking, 100 μl Na-citrate and 500 μl LB were added. Cultures were incubated at 37° C. or 32° C. for 45 or 60 minutes, respectively, then 3 ml of warm LB supplemented with 0.7% agar was added and the suspension was poured onto a plate containing the appropriate drug. Transductants obtained on antibiotic plates were streaked several times on selection plates and verified by PCR for the presence of the transduced DNA fragment.

MIC Determinations.

MIC determination was carried out by following the procedure described by Wiegand et al. (19). Briefly, bacterial cells were grown overnight at 32° C. in LB and diluted to 10⁷-10⁹ CFU/ml. The obtained suspension was serially diluted 10-fold for different spot concentrations, as indicated. Approximately 1 μl of bacterial suspension was then spotted onto selection plates containing different concentrations of either streptomycin or nalidixic acid along with the appropriate selection agent (chloramphenicol or tellurite), as indi-

21

cated, using a 48-pin replicator. Plates were incubated overnight and photographed using MiniBis Pro (Bio-Imaging Systems). Photographs were digitally manipulated using GIMP2 software to adjust contrast. Liquid-based MIC determination assays were carried out by inoculating serial dilutions of an antibiotic in liquid LB broth with bacterial cultures (OD₆₀₀ ~0.05) in 96-well microtiter plates. Plates were incubated overnight at 32° C. and OD₆₀₀ was then measured. The lowest antibiotic concentration at which the relative growth compared to the “no-drug” control was below 10% was determined as the MIC.

Example 1

Mutations in the Target Gene, *rpsL*, Constitute a Major Resistance Mechanism to Streptomycin

The overall goal of this study was to provide a proof-of-principle for a genetic system able to restore drug sensitivity to drug-resistant pathogens residing on hospital surfaces. The present inventors chose, as a first step, to use streptomycin as the model drug. Streptomycin is highly useful as an effective antibiotic against both Gram-negative and Gram-positive bacteria. For example, streptomycin is a mainstay of tuberculosis therapy. However, streptomycin-resistant *Mycobacterium tuberculosis* emerge during treatment, and 24 to 85.2% of them have mutations in either *rpsL* or *rrs* (15). The *rpsL* gene product, S12, is an essential, highly conserved protein of the 30S small ribosomal subunit. Most of the acquired resistance to streptomycin is due to specific mutations in *rpsL* that prevent the inhibitory binding of streptomycin to the essential *rpsL* gene product. The present inventors wanted to reproduce these findings in a model bacterium, *E. coli*, and then to restore its sensitivity to streptomycin. *E. coli* K-12 were inoculated on LB-agar plates containing 50 µg/ml streptomycin and resistant mutants were selected. This procedure fairly simulates the selection of spontaneous drug-resistant-mutant evolution in hospitals following streptomycin treatment. Resistant colonies emerged with a median frequency of 1 in 10⁹ CFU. Mutations in *rpsL* were found in 21 out of 22 resistant mutants, a frequency that corroborates with that in clinical isolates. As listed in Table 2, 10 mutants harbored a K88R substitution in *RpsL*, 6 had an R86S substitution, and P42S, K43L, K43N, R54S, K88E substitutions were each identified once. These mutation types also corroborate with previous studies, confirming that a major mechanism for streptomycin resistance relies on mutations in *rpsL* (e.g. (16, 18)). Therefore, the present inventors concluded that targeting this resistance mechanism or reversing its effect should prove highly beneficial in controlling drug-resistant pathogens.

Example 2

Wild-Type (wt) *rpsL* Transformed on a Plasmid Dominantly Confers Streptomycin Sensitivity

Minimum inhibitory concentration (MICs) to streptomycin were determined by agar-plate assay (19). In this assay, ~10⁴ cells are replica-plated on plates with different drug concentrations. The lowest concentration at which there is no visible colony-formation is defined as the MIC. The MICs throughout the study were also measured in a complementary liquid-determination assay, giving a similar readout (not shown). Two representatives of the most common streptomycin-resistant strains obtained above were taken for further study: strains Sm6 and Sm13, harboring mutations in *rpsL*

22

leading to substitutions of R86S and K88R, respectively. Their MICs to streptomycin were 100 µg/ml and 200 µg/ml, respectively, whereas the MIC of the parental strain was 1.56 µg/ml. These strains were transformed with the plasmid pRpsL-wt, encoding the wt *rpsL*, or a control plasmid, pRpsLΔ4, encoding a mock gene (a defective *rpsL* with a 4-bp deletion that disrupts the reading frame after amino acid 26 of the *RpsL* protein; see FIG. 1) under a modified early *E. coli* promoter from phage T7. Transformed cells were selected on agar plates supplemented with 35 µg/ml chloramphenicol, as the plasmid encodes chloramphenicol acetyl transferase, which confers chloramphenicol resistance. The MICs of the transformed strains to streptomycin were then determined. As shown in FIG. 2A, transformation of the plasmid encoding wt *rpsL*, pRpsL-wt, conferred a dominant sensitive phenotype, restoring the MIC of the resistant mutants Sm6 and Sm13 from 100 µg/ml to 12.5 µg/ml and from 200 µg/ml to 3.125 µg/ml, respectively. A control, streptomycin-sensitive *E. coli* transformed with these plasmids (pRpsLΔ4 or pRpsL-wt) retained similar MICs to streptomycin (not shown). These results demonstrate that a wt *rpsL* allele delivered via a plasmid into a streptomycin-resistant *E. coli* renders the cell significantly more sensitive to streptomycin.

Example 3

rpsL Designed with Decreased Homology to the wt Allele can Efficiently Restore Streptomycin Sensitivity

The present inventors propose that the *rpsL*-containing construct may be transferred horizontally between strains by transformation, conjugation or transduction, as described below. Recombination events between the chromosomal resistant *rpsL* and the delivered wt *rpsL* may reduce the efficiency of the construct because it may eventually recombine with an *rpsL* copy that does not confer sensitivity on the transformed strains (nevertheless, there is no danger that it will confer resistance in sensitive strains as the sensitive allele is dominant). In order to reduce the undesired recombination events between the incoming allele conferring sensitivity and the resistant allele in the transformed cell, the present inventors have designed an allele which cannot undergo homologous recombination with the bacterial copy. Efficient homologous recombination requires identity between recombining genes. Reduction of homology from 100% to 90% decreases the frequency of recombination over 40-fold in *E. coli* (14). In addition, a minimal efficient processing segment of 23 to 27 bp that is identical to the invading strand is required for efficient homologous recombination (14). The present inventors synthesized an *rpsL* gene with silent mutations that maximize the incompatibility of recombination with the sequence of wt *rpsL*. Silent substitutions were made in every possible case, except where codon usage was less than 10%. Overall, the genes were identical in only 62% of their sequence, and there was no single minimal efficient process segment between the wt *rpsL* and the new *rpsL* allele, thus providing efficient barriers against homologous recombination. This allele was designated *rpsL*-sil, and the plasmid encoding it, pRpsL-sil. The introduced silent mutations might hamper the folding of the encoded protein or its expression levels (3). Therefore, this allele was tested, like the wt *rpsL*, for its ability to dominantly restore sensitivity. As shown in FIG. 2B, dramatic sensitization to streptomycin was observed, with the MIC values decreasing in Sm6 and Sm13 from 100 µg/ml to 25 µg/ml and from 200 µg/ml to 6.25

23

μg/ml, respectively. The efficiency of restoration of sensitivity was lower than that observed with the wt rpsL, possibly due to the product's folding efficiency, as already mentioned. Nevertheless, these results indicate that both rpsL and rpsL-sil can efficiently restore sensitivity to streptomycin when expressed from plasmids.

Example 4

A Toxic Compound, Tellurite, Efficiently Replaces Chloramphenicol as a Selection Marker

In the above experiments, chloramphenicol, under the constitutive bla promoter, was used as a selection and maintenance marker for the rpsL-encoding plasmids. However, chloramphenicol is not a dispensable antibiotic, and by using it in the proposed system, sensitivity to streptomycin is restored by forfeiting sensitivity to chloramphenicol. This outcome is less desirable than one in which drug sensitivity is restored without forfeiting sensitivities to other drugs. The present inventors therefore sought to replace chloramphenicol with a dispensable, yet efficient, selection substance. A resistance gene against tellurite (TeO_3^{2-}), a toxic compound, was evaluated. Tellurite is toxic to bacteria as it forms long-lived sulfur complexes, thus disrupting the thiol balance in the bacterial cells. The tellurite-resistance genes, tehAB, present naturally in the *E. coli* chromosome, do not confer resistance to *E. coli* under their endogenous promoter due to low transcription (9). Upon expression from an active promoter (e.g. T7), however, the MIC of tellurite against *E. coli* increases 50- to 100-fold.

Plasmids encoding rpsL-sil or the mock gene were constructed, carrying the tellurite-resistance genes, tehAB, instead of the gene encoding chloramphenicol acetyl transferase. These plasmids were named pRpsL-sil-tell and pRpsLΔ4-tell. The plasmids were transformed into the streptomycin-resistant strains, Sm6 and Sm13, and the MICs of these transformed cells to streptomycin were determined. Restoration of sensitivity by tellurite-based plasmids was comparable to that observed with the chloramphenicol-based plasmids (FIG. 3). pRpsL-sil-tell sensitized Sm6 from a MIC of 100 μg/ml to 1.56 μg/ml, and Sm13 from a MIC of 200 μg/ml to 12.5 μg/ml. These results indicate that tellurite can be used instead of the chloramphenicol-resistance marker. They also demonstrate that tellurite can maintain the plasmids without cross-reactivity with the streptomycin-resistance phenotype.

Example 5

Streptomycin-Resistant Bacteria Lysogenized with Phage λ Encoding rpsL Become Streptomycin-Sensitive

The above experiments show that it is possible to restore drug sensitivity using plasmids as a genetic delivery tool without forfeiting other drugs' efficiencies. The present inventors next evaluated the use of phages as safer delivery vehicles for the designed constructs. We chose λ, a model phage which has been extensively studied, as a gene-delivery tool. This phage can infect its *E. coli* host and proceed to the lytic to or lysogenic cycle. A common phage mutant was used (λgt11, see Materials and Methods) which is directed to a specific cycle type according to the ambient temperature, and has a deletion (nin5) designed to allow stable insertion of up to 5 kb of foreign DNA. This phage mutant was engineered to contain wt rpsL, rpsL-sil, or a mock-rpsL, each linked to the

24

tellurite-resistance genes and designated, respectively, λ-RpsL-wt-tell, λ-RpsL-sil-tell, and λ-RpsLΔ4-tell. One of the streptomycin-resistant strains used above, Sm13, was lysogenized with the recombinant phages and selected on agar plates supplemented with 1.5 μg/ml tellurite at 32° C., a temperature at which it favors the lysogenic cycle. The lysogenized bacteria were propagated and their MICs to streptomycin determined. Lysogenization of Sm13 by the phages resulted in sensitization of the resistant mutants (FIG. 4A). The MIC value for the λ-RpsLΔ4-tell lysogen was 200 μg/ml, compared to 25 μg/ml and 50 μg/ml for λ-RpsL-wt-tell and λ-RpsL-sil-tell, respectively. Although significant, the sensitization was not as efficient as that observed using plasmid delivery.

Example 6

Two Copies of the rpsL Gene are Significantly More Efficient than a Single Copy in Reversing Resistance

It was suspected that the decreased sensitization observed by lysogenization relative to plasmid transformation was due to a lower number of rpsL gene copies introduced by the λ phage. To test this and improve the sensitization, the two different rpsL alleles (wt rpsL and rpsL-sil) were cloned into the λ phage, designated λ-2xRpsL-tell, which was used to lysogenize the resistant strain Sm13 as above. Introduction of two gene copies dramatically enhanced the sensitization efficiency of the lysogenized strains, resulting in a significant decrease of the MIC from 200 μg/ml to 1.56 μg/ml, comparable to the MIC observed for the sensitive strain (FIG. 4B). As a whole, these results constitute a proof-of-principle for restoration of sensitivity to streptomycin using a phage that carries sufficient copies of rpsL, at the "genetic cost" of a resistance marker to a toxic compound.

Example 7

Nalidixic Acid-Resistant Bacteria Lysogenized with Phage λ Encoding gyrA Show Restored Nalidixic Acid Sensitivity

The above results demonstrate that streptomycin resistance can be reversed by the proposed system. The present inventors wished to expand the proof-of-principle to other antibiotics as well, to demonstrate that a "multidrug-sensitivity cassette" can theoretically be used. Quinolone resistance was targeted, which also manifests dominant sensitivity by the wt allele (12). The quinolone drug family targets the enzyme gyrase, encoded by gyrA, resulting in DNA-replication arrest. Mutations in gyrA are observed in a specific region termed "quinolone-resistance-determining region" (QRDR). The wt gyrA allele is dominant sensitive and may therefore reverse resistance (12). Nalidixic acid, the first of the synthetic quinolone family antibiotics, was used here as a representative of the quinolone family. To test whether the system can restore sensitivity to quinolone, spontaneous nalidixic acid-resistant mutants were isolated by plating sensitive *E. coli* on 50 μg/ml nalidixic acid. Similar to the isolation of the streptomycin mutants, mutants were obtained with previously reported substitutions in the target gene, gyrA (Table 3). Five D87G substitutions and three S83L substitutions in the gyrA gene product were identified. These results corroborate another study on pathogenic *E. coli*, which showed that 37 out of 38 isolated quinolone-resistant gyrA mutants have substitutions at either S83 or D87 or both. Out of 36 pathogenic *E. coli* resistant to high levels of nalidixic acid (MIC≥256

25

μg/ml), 35 had at least one mutation in *gyrA* (4). Here, as with the isolation of streptomycin-resistant mutants, the fact that most of the spontaneous mutants are located in the target gene highlights the potential benefit of reversing the effect of these mutations. The present inventors next introduced the wt *gyrA* expressed from its endogenous promoter, or a control construct, both linked to tellurite-resistance genes, into λ phages, designated λ-GyrA-tell and λ-Ctrl-tell respectively. These phages were used to lysogenize a nalidixic acid-resistant strain, Nal2, harboring a S83L substitution in *GyrA*. The lysogens were selected on 4 μg/ml tellurite and tested for sensitization by measuring MICs as described above, using nalidixic acid instead of streptomycin. As shown in FIG. 5, the *gyrA* construct significantly reversed the mutant's resistance. The MIC of the resistant mutants decreased twofold when lysogenized by a *gyrA*-encoding phage compared to the control phage. The significance of this sensitization was corroborated by experiments in which *gyrA*-encoding plasmids were transformed into nalidixic acid-resistant mutants. A three orders of magnitude decrease in the number of CFU on 50 μg/ml nalidixic acid was observed compared to resistant cells transformed with a mock plasmid (FIG. 6). Overall, these results indicate that the proposed system can be used to target nalidixic acid resistance as well as streptomycin resistance.

Example 8

Proposed Application, Safety Measures, and Advantages of the System

The proof-of-principle presented here is a step toward solving the major threat of emerging drug-resistant pathogens, against which there are limited new emerging antibiotic weapons. It demonstrates that with simple genetic engineering, bacteria can be resensitized to approved and useful antibiotics. According to one embodiment, the system can be applied in a simple treatment of hospital surfaces to reverse the resistance of nosocomial pathogens.

The proposed uses and advantages of the system are presented in Table 5, herein below.

26

TABLE 5

Advantage of proposed procedure	Proposed procedure	Current procedure	Surface treatment/frequency	
Renders bacteria drug-sensitive	V	V	Soap	Floor/furniture cleansing
Selects for drug-sensitive residual bacteria to occupy ecological niche	V	X	Lysogenizing phages	Disinfection
Repeated usage results in more sensitive clones	V	X	Tellurite	
	V	V	Daily	Frequency

Extended transfer of the sensitizing cassette by specifically constructed lysogenizing phages might enrich for antibiotic-treatable pathogens on hospital surfaces. This enriched, sensitive population might then interfere with the establishment of newly introduced resistant pathogens by overtaking their ecological niche. The present approach differs from conventional phage therapy in the sense that it does not use phages to kill the pathogens directly. Consequently, there is no selection against the used phage, but rather selection for pathogens harboring the phage because it contains tellurite resistance. Moreover, the approach avoids the use of phages inside the patient's body, thus overcoming toxicity issues and other drawbacks of phage therapy, such as phage neutralization by the spleen and the immune system (11).

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 32

<210> SEQ ID NO 1

<211> LENGTH: 74

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 1

caataaccct gataaatgct tcaataatat tgaaaaagga agagtactag tatgcagagc 60

gataaagtgc tcaa 74

<210> SEQ ID NO 2

<211> LENGTH: 74

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 2

 aagttttaa tcaatctaaa gtatatatga gtaaacttgg tctgacagct cgagtcattt 60
 tttacgtgcc agca 74

 <210> SEQ ID NO 3
 <211> LENGTH: 80
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 3

 tcgttttaca acgtcgtgga tccttacc aa tgcttaataca gtgaggctcg gattatcaaa 60
 aaggatcttc acctagatcc 80

 <210> SEQ ID NO 4
 <211> LENGTH: 88
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 4

 acttaagctt aaaagagtat tgacttaaag tctaactata ggatacttac agccatagga 60
 ggacagctat ggcaacagtt aaccagct 88

 <210> SEQ ID NO 5
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 5

 ttcggaattc ttaagcctta ggacgcttca 30

 <210> SEQ ID NO 6
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 6

 gctagaattc ggcgacggct tcaaatttag 30

 <210> SEQ ID NO 7
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 7

 catatggtat tcttctctctg gctcgtc 27

 <210> SEQ ID NO 8
 <211> LENGTH: 30
 <212> TYPE: DNA

-continued

<213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 8

 actttctaga aggaaacagc tatgaccatg 30

<210> SEQ ID NO 9
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 9

 taacggatcc ttaccaatgc ttaatcagtg 30

<210> SEQ ID NO 10
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 10

 taacggatcc acgacgttgt aaaacgacgg 30

<210> SEQ ID NO 11
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 11

 actttctaga aggtgaagat cctttttgat 30

<210> SEQ ID NO 12
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 12

 acgccaattg gtatggttg tggaattgtg 30

<210> SEQ ID NO 13
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 13

 cgttcaattg gttaaggat tttggtcatg 30

<210> SEQ ID NO 14
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

 <400> SEQUENCE: 14

 cagacatgta taccctgtac 20

-continued

<210> SEQ ID NO 15
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 15

tacgccatgg ccggagtggc 20

<210> SEQ ID NO 16
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 16

gtgtgaaatt gttatccgct 20

<210> SEQ ID NO 17
 <211> LENGTH: 34
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 17

actgactagt actcttcctt tttcaatatt attg 34

<210> SEQ ID NO 18
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 18

ctgtcagacc aagtttactc ctgtcagacc aagtttactc 40

<210> SEQ ID NO 19
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 19

actgactagt atggagaaaa aaatcactgg 30

<210> SEQ ID NO 20
 <211> LENGTH: 31
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 20

ttcactcgag ttacgccccg ccctgccact c 31

<210> SEQ ID NO 21
 <211> LENGTH: 47
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 21

aaaagagtat tgacttaaag tctaacctat aggatactta cagccat 47

<210> SEQ ID NO 22

<211> LENGTH: 46

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Single strand DNA oligonucleotides

<400> SEQUENCE: 22

aaaagagtat tgacttaaag tctaactata ggatacttac agccat 46

<210> SEQ ID NO 23

<211> LENGTH: 375

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: E. Coli derived wildtype rpsL

<400> SEQUENCE: 23

atggcaacag ttaaccagct ggtacgcaaa ccacgtgctc gcaaagttgc gaaaagcaac 60

gtgctcgcgc tggaaagcatg cccgcaaaaa cgtggcggtat gtactcgtgt atatactacc 120

actcctaaaa aaccgaactc cgcgctgcgt aaagtatgcc gtgttcgtct gactaacggt 180

ttcgaagtga cttcctacat cgggtggtgaa ggtcacaacc tgcaggagca ctccgtgatc 240

ctgatccgtg gcggtcgtgt taaagacctc ccgggtgttc gttaccacac cgtacgtggt 300

gcgcttgact gctccggcgt taaagaccgt aagcaggctc gttccaagta tggcgtgaag 360

cgtcctaagg cttaa 375

<210> SEQ ID NO 24

<211> LENGTH: 375

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: An exemplary polynucleotide sequence encoding wild-type 30S ribosomal subunit protein S12 (RpsL), modified so as to prevent homologous recombination

<400> SEQUENCE: 24

atggcgaccg tgaatcaatt agtgcgtaag ccgcgcgcgc gtaaggtggc aaagtcgaat 60

gttccggcct tagaggcgtg tccacagaag cgcggtgtgt gcacccgcgt gtacaccacg 120

acccgaaga agccaaatag tgccttacgc aaggtgtgtc gcgtgcgctt aacgaatggc 180

tttgaggtta ccagttatat tggcggcgag ggccataatt tacaagaaca tagtgttatt 240

ttaattcgcg gtggccgcgt gaaggatttg ccaggcgtgc gctatcatac ggtgcgcggc 300

gccttgatt gtagtggtgt gaaggatcgc aaacaagcgc gcagtaaata cgggtgtaaa 360

cgcccgaag cgtga 375

<210> SEQ ID NO 25

<211> LENGTH: 124

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: RPSL wild-type amino acid sequence

<400> SEQUENCE: 25

Met Ala Thr Val Asn Gln Leu Val Arg Lys Pro Arg Ala Arg Lys Val

-continued

1	5	10	15
Ala Lys Ser Asn Val Pro Ala Leu Glu Ala Cys Pro Gln Lys Arg Gly	20	25	30
Val Cys Thr Arg Val Tyr Thr Thr Thr Pro Lys Lys Pro Asn Ser Ala	35	40	45
Leu Arg Lys Val Cys Arg Val Arg Leu Thr Asn Gly Phe Glu Val Thr	50	55	60
Ser Tyr Ile Gly Gly Glu Gly His Asn Leu Gln Glu His Ser Val Ile	65	70	75
Leu Ile Arg Gly Gly Arg Val Lys Asp Leu Pro Gly Val Arg Tyr His	85	90	95
Thr Val Arg Gly Ala Leu Asp Cys Ser Gly Val Lys Asp Arg Lys Gln	100	105	110
Ala Arg Ser Lys Tyr Gly Val Lys Arg Pro Lys Ala	115	120	

<210> SEQ ID NO 26

<211> LENGTH: 2628

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: E. coli derived gyrA coding sequence

<400> SEQUENCE: 26

```

atgagcgcacc ttgcgagaga aattacaccg gtcaacattg aggaagagct gaagagctcc      60
tatctggatt atgcgatgtc ggtcattggt ggccgtgccc tgccagatgt ccgagatggc      120
ctgaagccgg tacaccgtcg cgtactttac gccatgaacg tactaggcaa tgactggaac      180
aaagcctata aaaaatctgc ccgtgtcggt ggtgacgtaa tcggtaaata ccatccccat      240
ggtgactcgg cggctctatga cacgatcgtc cgcattggcg agccattctc gctgcggtat      300
atgctggtag acggtcaggg taacttcggt tctatcgacg gcgactctgc ggccggcaatg      360
cgttataccg aatccgtct ggccgaaaatt gccatgaac tgatggccga tctcgaaaaa      420
gagacggtcg atttcgttga taactatgac ggacggaaa aaattccgga cgtcatgcca      480
acaaaattc ctaacctgct ggtgaacggt tcttccggtg tcgccgtagg tatggcaacc      540
aacatccccg cgcacaacct gacggaagtc atcaacgggt gtctggcgta tattgatgat      600
gaagacatca gcattgaagg gctgatggaa cacatcccgg ggccggactt cccgacggcg      660
gcaatcatta acggtcgtcg cggattgaa gaagcttacc gtaccggtcg cggcaagggtg      720
tatatccgcg ctgcgcgaga agtggaagtt gacgccaaaa ccggtcgtga aaccattatc      780
gtccacgaaa ttccgtatca ggtaaacaaa gcgcgcctga tcgagaagat tgcggaactg      840
gtaaaagaaa aacgcgtgga aggcattcagc gcgctgcgtg acgagtctga caaagacgggt      900
atgcgcatcg tgattgaagt gaaacgcgat gcggtcgggt aagttgtgct caacaacctc      960
tactcccaga ccagttgca ggtttctttc ggtatcaaca tgggtggcatt gcacctgggt      1020
cagccgaaga tcatgaacct gaaagacatc atcgcggcgt ttgttcgtca ccgccgtgaa      1080
gtggtgacct gtcgtactat tttcgaactg cgtaaagctc gcgatcgtgc tcatatcctt      1140
gaagcattag ccgtggcgct ggccgaacatc gaccgatca tcgaactgat ccgtcatgcg      1200
ccgacgcctg cagaagcgaa aactgcgctg gttgctaate cgtggcagct gggcaacggt      1260
gccgcgatgc tcgaacgtgc tggcgacgat gctgcgcgtc cggaatgggt ggagccagag      1320
ttcggcgtgc gtgatggtct gtactacctg accgaacagc aagctcaggc gattctggat      1380

```

-continued

```

ctgcgtttgc agaaactgac cggctcttgag cacgaaaaac tgctcgacga atacaaagag 1440
ctgctggatc agatcgcgga actggttgcgt attcttggta gcgccgatcg tctgatggaa 1500
gtgatccgtg aagagctgga gctggttcgt gaacagttcg gtgacaaaac tcgtactgaa 1560
atcaccccca acagcgaga catcaacctg gaagatctga tcaccagga agatgtggtc 1620
gtgacgctct ctcaccagg ctacgttaag tatcagccgc tttctgaata cgaagcgag 1680
cgtcgtggcg ggaaaggtaa atctgccgca cgtattaaag aagaagactt tatcgaccga 1740
ctgctggtgg cgaacactca cgaccatatt ctgtgcttct ccagccgtgg tcgctctat 1800
tcgatgaaag tttatcagtt gccggaagcc actcgtggcg cgcgcggtcg tccgatcgtc 1860
aacctgctgc cgctggagca ggacgaacgt atcactgcca tcctgccagt gaccgagttt 1920
gaagaaggcg tgaagtctt catggcgacc gctaaccgta ccgtgaagaa aactgtcctc 1980
accgagttca accgtctgcg taccgccggt aaagtggcga tcaaactggt tgacggcgat 2040
gagctgatcg gcgttgacct gaccagcggc gaagacgaag taatgctgtt ctccgctgaa 2100
ggtaaagtgg tgcgctttaa agagtcttct gtccgtgcca tgggctgcaa caccaccggt 2160
gttcgcggta ttcgcttagg tgaaggcgat aaagtctct ctctgatcgt gcctcgtggc 2220
gatggcgcaa tcctcaccgc aacgcaaac ggttacgga aacgtaccgc agtggcgga 2280
taccacaacca agtcgctgac gacgaaaggg gttatctcca tcaaggttac cgaacgtaac 2340
ggtttagttg ttggcgcggt acaggtagat gactgcgacc agatcatgat gatcaccgat 2400
gccggtacgc tggtagtac tcgctttcgc gaaatcagca tcgtgggccc taacaccag 2460
ggcgtgatcc tcatccgtac tgcggaagat gaaaacgtag tgggtctgca acgtgttgct 2520
gaaccggttg acgaggaaga tctggatacc atcgacggca gtgcccgga aggggacgat 2580
gaaatcgctc cggaagtgga cgttgacgac gagccagaag aagaataa 2628

```

<210> SEQ ID NO 27

<211> LENGTH: 875

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: WT gyrase protein

<400> SEQUENCE: 27

```

Met Ser Asp Leu Ala Arg Glu Ile Thr Pro Val Asn Ile Glu Glu Glu
1           5           10          15
Leu Lys Ser Ser Tyr Leu Asp Tyr Ala Met Ser Val Ile Val Gly Arg
20          25          30
Ala Leu Pro Asp Val Arg Asp Gly Leu Lys Pro Val His Arg Arg Val
35          40          45
Leu Tyr Ala Met Asn Val Leu Gly Asn Asp Trp Asn Lys Ala Tyr Lys
50          55          60
Lys Ser Ala Arg Val Val Gly Asp Val Ile Gly Lys Tyr His Pro His
65          70          75          80
Gly Asp Ser Ala Val Tyr Asp Thr Ile Val Arg Met Ala Gln Pro Phe
85          90          95
Ser Leu Arg Tyr Met Leu Val Asp Gly Gln Gly Asn Phe Gly Ser Ile
100         105         110
Asp Gly Asp Ser Ala Ala Ala Met Arg Tyr Thr Glu Ile Arg Leu Ala
115         120         125
Lys Ile Ala His Glu Leu Met Ala Asp Leu Glu Lys Glu Thr Val Asp
130         135         140

```

-continued

Phe	Val	Asp	Asn	Tyr	Asp	Gly	Thr	Glu	Lys	Ile	Pro	Asp	Val	Met	Pro	145	150	155	160
Thr	Lys	Ile	Pro	Asn	Leu	Leu	Val	Asn	Gly	Ser	Ser	Gly	Ile	Ala	Val	165	170	175	
Gly	Met	Ala	Thr	Asn	Ile	Pro	Pro	His	Asn	Leu	Thr	Glu	Val	Ile	Asn	180	185	190	
Gly	Cys	Leu	Ala	Tyr	Ile	Asp	Asp	Glu	Asp	Ile	Ser	Ile	Glu	Gly	Leu	195	200	205	
Met	Glu	His	Ile	Pro	Gly	Pro	Asp	Phe	Pro	Thr	Ala	Ala	Ile	Ile	Asn	210	215	220	
Gly	Arg	Arg	Gly	Ile	Glu	Glu	Ala	Tyr	Arg	Thr	Gly	Arg	Gly	Lys	Val	225	230	235	240
Tyr	Ile	Arg	Ala	Arg	Ala	Glu	Val	Glu	Val	Asp	Ala	Lys	Thr	Gly	Arg	245	250	255	
Glu	Thr	Ile	Ile	Val	His	Glu	Ile	Pro	Tyr	Gln	Val	Asn	Lys	Ala	Arg	260	265	270	
Leu	Ile	Glu	Lys	Ile	Ala	Glu	Leu	Val	Lys	Glu	Lys	Arg	Val	Glu	Gly	275	280	285	
Ile	Ser	Ala	Leu	Arg	Asp	Glu	Ser	Asp	Lys	Asp	Gly	Met	Arg	Ile	Val	290	295	300	
Ile	Glu	Val	Lys	Arg	Asp	Ala	Val	Gly	Glu	Val	Val	Leu	Asn	Asn	Leu	305	310	315	320
Tyr	Ser	Gln	Thr	Gln	Leu	Gln	Val	Ser	Phe	Gly	Ile	Asn	Met	Val	Ala	325	330	335	
Leu	His	His	Gly	Gln	Pro	Lys	Ile	Met	Asn	Leu	Lys	Asp	Ile	Ile	Ala	340	345	350	
Ala	Phe	Val	Arg	His	Arg	Arg	Glu	Val	Val	Thr	Arg	Arg	Thr	Ile	Phe	355	360	365	
Glu	Leu	Arg	Lys	Ala	Arg	Asp	Arg	Ala	His	Ile	Leu	Glu	Ala	Leu	Ala	370	375	380	
Val	Ala	Leu	Ala	Asn	Ile	Asp	Pro	Ile	Ile	Glu	Leu	Ile	Arg	His	Ala	385	390	395	400
Pro	Thr	Pro	Ala	Glu	Ala	Lys	Thr	Ala	Leu	Val	Ala	Asn	Pro	Trp	Gln	405	410	415	
Leu	Gly	Asn	Val	Ala	Ala	Met	Leu	Glu	Arg	Ala	Gly	Asp	Asp	Ala	Ala	420	425	430	
Arg	Pro	Glu	Trp	Leu	Glu	Pro	Glu	Phe	Gly	Val	Arg	Asp	Gly	Leu	Tyr	435	440	445	
Tyr	Leu	Thr	Glu	Gln	Gln	Ala	Gln	Ala	Ile	Leu	Asp	Leu	Arg	Leu	Gln	450	455	460	
Lys	Leu	Thr	Gly	Leu	Glu	His	Glu	Lys	Leu	Leu	Asp	Glu	Tyr	Lys	Glu	465	470	475	480
Leu	Leu	Asp	Gln	Ile	Ala	Glu	Leu	Leu	Arg	Ile	Leu	Gly	Ser	Ala	Asp	485	490	495	
Arg	Leu	Met	Glu	Val	Ile	Arg	Glu	Glu	Leu	Glu	Leu	Val	Arg	Glu	Gln	500	505	510	
Phe	Gly	Asp	Lys	Arg	Arg	Thr	Glu	Ile	Thr	Ala	Asn	Ser	Ala	Asp	Ile	515	520	525	
Asn	Leu	Glu	Asp	Leu	Ile	Thr	Gln	Glu	Asp	Val	Val	Val	Thr	Leu	Ser	530	535	540	
His	Gln	Gly	Tyr	Val	Lys	Tyr	Gln	Pro	Leu	Ser	Glu	Tyr	Glu	Ala	Gln	545	550	555	560
Arg	Arg	Gly	Gly	Lys	Gly	Lys	Ser	Ala	Ala	Arg	Ile	Lys	Glu	Glu	Asp				

-continued

565				570				575							
Phe	Ile	Asp	Arg	Leu	Leu	Val	Ala	Asn	Thr	His	Asp	His	Ile	Leu	Cys
			580								585			590	
Phe	Ser	Ser	Arg	Gly	Arg	Val	Tyr	Ser	Met	Lys	Val	Tyr	Gln	Leu	Pro
			595				600							605	
Glu	Ala	Thr	Arg	Gly	Ala	Arg	Gly	Arg	Pro	Ile	Val	Asn	Leu	Leu	Pro
			610				615							620	
Leu	Glu	Gln	Asp	Glu	Arg	Ile	Thr	Ala	Ile	Leu	Pro	Val	Thr	Glu	Phe
			625				630				635				640
Glu	Glu	Gly	Val	Lys	Val	Phe	Met	Ala	Thr	Ala	Asn	Gly	Thr	Val	Lys
			645								650			655	
Lys	Thr	Val	Leu	Thr	Glu	Phe	Asn	Arg	Leu	Arg	Thr	Ala	Gly	Lys	Val
			660								665			670	
Ala	Ile	Lys	Leu	Val	Asp	Gly	Asp	Glu	Leu	Ile	Gly	Val	Asp	Leu	Thr
			675				680							685	
Ser	Gly	Glu	Asp	Glu	Val	Met	Leu	Phe	Ser	Ala	Glu	Gly	Lys	Val	Val
			690				695				700				
Arg	Phe	Lys	Glu	Ser	Ser	Val	Arg	Ala	Met	Gly	Cys	Asn	Thr	Thr	Gly
			705				710				715				720
Val	Arg	Gly	Ile	Arg	Leu	Gly	Glu	Gly	Asp	Lys	Val	Val	Ser	Leu	Ile
			725								730				735
Val	Pro	Arg	Gly	Asp	Gly	Ala	Ile	Leu	Thr	Ala	Thr	Gln	Asn	Gly	Tyr
			740								745				750
Gly	Lys	Arg	Thr	Ala	Val	Ala	Glu	Tyr	Pro	Thr	Lys	Ser	Arg	Ala	Thr
			755				760							765	
Lys	Gly	Val	Ile	Ser	Ile	Lys	Val	Thr	Glu	Arg	Asn	Gly	Leu	Val	Val
			770				775				780				
Gly	Ala	Val	Gln	Val	Asp	Asp	Cys	Asp	Gln	Ile	Met	Met	Ile	Thr	Asp
			785				790				795				800
Ala	Gly	Thr	Leu	Val	Arg	Thr	Arg	Val	Ser	Glu	Ile	Ser	Ile	Val	Gly
			805								810				815
Arg	Asn	Thr	Gln	Gly	Val	Ile	Leu	Ile	Arg	Thr	Ala	Glu	Asp	Glu	Asn
			820								825			830	
Val	Val	Gly	Leu	Gln	Arg	Val	Ala	Glu	Pro	Val	Asp	Glu	Glu	Asp	Leu
			835				840							845	
Asp	Thr	Ile	Asp	Gly	Ser	Ala	Ala	Glu	Gly	Asp	Asp	Glu	Ile	Ala	Pro
			850				855				860				
Glu	Val	Asp	Val	Asp	Asp	Glu	Pro	Glu	Glu	Glu					
			865				870				875				

<210> SEQ ID NO 28

<211> LENGTH: 4029

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: E. coli derived rpoB coding sequence

<400> SEQUENCE: 28

```

atggtttact cctataccga gaaaaaacgt attcgtaagg attttggtaa acgtccacaa    60
gttctggatg taccttatct cctttctatc cagcttgact cgtttcagaa atttatcgag    120
caagatcctg aagggcagta tggctctggaa gctgctttcc gttecgattt cccgattcag    180
agctacagcg gtaattccga gctgcaatac gtcagctacc gccttggcga accggtgttt    240
gacgtccagg aatgtcaaat ccgtggcgtg acctattccg caccgctgcg cggttaaactg    300

```

-continued

cgtctggtga	tctatgagcg	cgaagcgccg	gaaggcaccg	taaaagacat	taaagaacaa	360
gaagtctaca	tgggcgaaat	tccgctcatg	acagacaacg	gtacctttgt	tatcaacggt	420
actgagcgtg	ttatcgtttc	ccagctgcac	cgtagtccgg	gcgtcttctt	tgactccgac	480
aaaggtaaaa	cccactcttc	gggtaaagtg	ctgtataacg	cgcgatcat	cccttacggt	540
ggttcctggc	tggacttcga	attcgatccg	aaggacaacc	tgttcgtacg	tatcgaccgt	600
cgccgtaaac	tgccctgcgac	catcattctg	cgcgccctga	actacaccac	agagcagatc	660
ctcgacctgt	tctttgaaaa	agttatcttt	gaaatccgtg	ataacaagct	gcagatggaa	720
ctggtgccgg	aacgcctgcg	tggtgaaacc	gcatcttttg	acatcgaagc	taacggtaaa	780
gtgtacgtag	aaaaaggccg	ccgtatcact	gcgcgccaca	ttcgccagct	ggaaaaagac	840
gacgtcaaac	tgatcgaagt	cccggttgag	tacatcgcag	gtaaagtggg	tgctaaagac	900
tatattgatg	agtctaccgg	cgagctgatc	tgcgacgcca	acatggagct	gagcctggat	960
ctgctggcta	agctgagcca	gtctggtcac	aagcgtatcg	aaacgctggt	caccaacgat	1020
ctggatcacg	gcccataat	ctctgaaacc	ttacgtgtcg	acccaactaa	cgaccgtctg	1080
agcgcactgg	tagaaatcta	ccgcatgatg	cgccctggcg	agccgcccac	tcgtgaagca	1140
gctgaaagcc	tgttcgagaa	cctggtcttc	tccgaagacc	gttatgactt	gtctgcgggt	1200
ggtcgtatga	agttcaaccg	ttctctgctg	cgcgaaagaa	tcaaggttc	cggtatcctg	1260
agcaaagacg	acatcattga	tgttatgaaa	aagctcatcg	atatccgtaa	cggtaaaggg	1320
gaagtcgatg	atategacca	cctcggcaac	cgctgatcc	gttccgttgg	cgaaatggcg	1380
gaaaaccagt	tccgcgttgg	cctggtacgt	gtagagcgtg	cggtgaaaga	gcgtctgtct	1440
ctgggcgatc	tggataccct	gatgccacag	gatatgatca	acgccaagcc	gatttccgca	1500
gcagtgaaag	agttcttcgg	ttccagccag	ctgtctcagt	ttatggacca	gaacaaccgg	1560
ctgtctgaga	ttacgcacaa	acgtcgtatc	tccgcactcg	gcccaggcgg	tctgaccctg	1620
gaacgtgcag	gcttcgaagt	tcgagacgta	caccgcactc	actacggtcg	cgatgtcca	1680
atcgaaaccc	ctgaaggtcc	gaacatcggg	ctgatcaact	ctctgtccgt	gtacgcacag	1740
actaacgaat	acggcttcct	tgagactccg	tatcgtaaag	tgaccgacgg	tggtgtaact	1800
gacgaaattc	actacctgtc	tgctatcgaa	gaaggcaact	acgttatcgc	ccaggcgaac	1860
tccaacttgg	atgaagaagg	ccacttcgta	gaagacctgg	taacttgccc	tagcaaaggg	1920
gaatccagct	tgttcagccg	cgaccagggt	gactacatgg	acgtatccac	ccagcagggtg	1980
gtatccgtcg	gtgcgtccct	gatcccgttc	ctggaacacg	atgacgcca	ccgtgcattg	2040
atgggtgcga	acatgcaacg	tcaggccggt	ccgactctgc	gcgctgataa	gccgctgggt	2100
ggtactggta	tggaacgtgc	tggtgcccgt	gactccgggtg	taactgcggg	agctaaacgt	2160
ggtggtgtcg	ttcagtacgt	ggatgcttcc	cgatcggtta	tcaaagttaa	cgaagacgag	2220
atgtatccgg	gtgaagcagg	tatcgacatc	tacaacctga	ccaaatacac	ccgttctaac	2280
cagaacacct	gtatcaacca	gatgccgtgt	gtgtctctgg	gtgaaccggt	tgaacgtggc	2340
gacgtgctgg	cagacgggtc	gtccaccgac	ctcgggtgaa	tgccgcttgg	tcagaacatg	2400
cgcgtagcgt	tcatgccgtg	gaatggttac	aacttcgaag	actccatcct	cgatccgag	2460
cgtggtgttc	aggaagaccg	tttcaccacc	atccacattc	aggaactggc	gtgtgtgtcc	2520
cgtgacacca	agctgggtcc	ggaagagatc	accgctgaca	tcccgaacgt	gggtgaagct	2580
gcgctctcca	aactggatga	atccggatc	gtttacattg	gtgcggaagt	gaccgggtggc	2640
gacattctgg	ttggtaaggt	aacgcccga	ggtgaaactc	agctgacccc	agaagaaaa	2700

-continued

```

ctgctgcgtg cgatcttcgg tgagaaagcc tctgacgta aagactcttc tctgcgcgta 2760
ccaaaacggtg tatccggtac ggttatcgac gttcaggtct ttactcgca tggcgtagaa 2820
aaagacaaac gtgcgctgga aatcgaagaa atgcagctca aacaggcgaa gaaagacctg 2880
tctgaagaac tgcagatcct cgaagcgggt ctgttcagcc gstatcctgc tgtgctggta 2940
gccggtggcg ttgaagctga gaagctcgac aaactgccgc gcgatcgctg gctggagctg 3000
ggcctgacag acgaagagaa acaaaatcag ctggaacagc tggctgagca gtatgacgaa 3060
ctgaaacacg agttcgagaa gaaactcgaa gcgaaacgcc gcaaaatcac ccagggcgac 3120
gatctggcac cgggcgtgct gaagattggt aaggtatatac tggcgggtaa acgccgtatc 3180
cagcctggtg acaagatggc aggtcgtcac ggtaacaagg gtgtaatttc taagatcaac 3240
ccgatcgaag atatgcctta cgatgaaaac ggtacgccgg tagacatcgt actgaaccgg 3300
ctgggcgtac cgtctcgtat gaacatcggg cagatcctcg aaaccacac gggatggct 3360
gcgaaaggta tcggcgacaa gatcaacgcc atgctgaaac agcagcaaga agtcgcgaaa 3420
ctgcgcgaat tcatccagcg tgcgtacgat ctgggcgctg acgttcgtca gaaagttgac 3480
ctgagtacct tcagcgatga agaagttatg cgtctggctg aaaacctgcg caaaggtatg 3540
ccaatcgcaa cgccggtggt cgacggtgcg aaagaagcag aaattaaaga gctgctgaaa 3600
cttggcgacc tgccgacttc cggtcagatc cgctgtacg atggtcgcac tgggtaacag 3660
ttcgagcgtc cggtaaccgt tggttacatg tacatgctga aactgaacca cctggtcgac 3720
gacaagatgc acgcgcgttc caccggttct tacagcctgg ttactcagca gccgctgggt 3780
ggtaaggcac agttcgtggg tcagcgtttc ggggagatgg aagtgtgggc gctggaagca 3840
tacggcgag cataccacct gcaggaaatg ctaccggtta agtctgatga cgtgaacggg 3900
cgtaccaaga tgtataaaaa catcgtggac ggcaaccatc agatggagcc gggcatgcca 3960
gaatccttca acgtattggt gaaagagatt cgttcgctgg gtatcaacat cgaactggaa 4020
gacgagtaa 4029

```

<210> SEQ ID NO 29

<211> LENGTH: 1282

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: WT RNA Polymerase Beta

<400> SEQUENCE: 29

```

Ser Tyr Ser Gly Asn Ser Glu Leu Gln Tyr Val Ser Tyr Arg Leu Gly
1           5           10           15
Glu Pro Val Phe Asp Val Gln Glu Cys Gln Ile Arg Gly Val Thr Tyr
20           25           30
Ser Ala Pro Leu Arg Val Lys Leu Arg Leu Val Ile Tyr Glu Arg Glu
35           40           45
Ala Pro Glu Gly Thr Val Lys Asp Ile Lys Glu Gln Glu Val Tyr Met
50           55           60
Gly Glu Ile Pro Leu Met Thr Asp Asn Gly Thr Phe Val Ile Asn Gly
65           70           75           80
Thr Glu Arg Val Ile Val Ser Gln Leu His Arg Ser Pro Gly Val Phe
85           90           95
Phe Asp Ser Asp Lys Gly Lys Thr His Ser Ser Gly Lys Val Leu Tyr
100          105          110
Asn Ala Arg Ile Ile Pro Tyr Arg Gly Ser Trp Leu Asp Phe Glu Phe

```


-continued

115				120				125							
Asp	Pro	Lys	Asp	Asn	Leu	Phe	Val	Arg	Ile	Asp	Arg	Arg	Arg	Lys	Leu
130				135		135				140					
Pro	Ala	Thr	Ile	Ile	Leu	Arg	Ala	Leu	Asn	Tyr	Thr	Thr	Glu	Gln	Ile
145				150					155					160	
Leu	Asp	Leu	Phe	Phe	Glu	Lys	Val	Ile	Phe	Glu	Ile	Arg	Asp	Asn	Lys
			165						170				175		
Leu	Gln	Met	Glu	Leu	Val	Pro	Glu	Arg	Leu	Arg	Gly	Glu	Thr	Ala	Ser
			180						185				190		
Phe	Asp	Ile	Glu	Ala	Asn	Gly	Lys	Val	Tyr	Val	Glu	Lys	Gly	Arg	Arg
		195				200							205		
Ile	Thr	Ala	Arg	His	Ile	Arg	Gln	Leu	Glu	Lys	Asp	Asp	Val	Lys	Leu
		210				215					220				
Ile	Glu	Val	Pro	Val	Glu	Tyr	Ile	Ala	Gly	Lys	Val	Val	Ala	Lys	Asp
225				230						235					240
Tyr	Ile	Asp	Glu	Ser	Thr	Gly	Glu	Leu	Ile	Cys	Ala	Ala	Asn	Met	Glu
			245						250					255	
Leu	Ser	Leu	Asp	Leu	Leu	Ala	Lys	Leu	Ser	Gln	Ser	Gly	His	Lys	Arg
			260						265				270		
Ile	Glu	Thr	Leu	Phe	Thr	Asn	Asp	Leu	Asp	His	Gly	Pro	Tyr	Ile	Ser
		275					280						285		
Glu	Thr	Leu	Arg	Val	Asp	Pro	Thr	Asn	Asp	Arg	Leu	Ser	Ala	Leu	Val
		290				295					300				
Glu	Ile	Tyr	Arg	Met	Met	Arg	Pro	Gly	Glu	Pro	Pro	Thr	Arg	Glu	Ala
305				310						315					320
Ala	Glu	Ser	Leu	Phe	Glu	Asn	Leu	Phe	Phe	Ser	Glu	Asp	Arg	Tyr	Asp
			325						330					335	
Leu	Ser	Ala	Val	Gly	Arg	Met	Lys	Phe	Asn	Arg	Ser	Leu	Leu	Arg	Glu
			340						345				350		
Glu	Ile	Glu	Gly	Ser	Gly	Ile	Leu	Ser	Lys	Asp	Asp	Ile	Ile	Asp	Val
		355				360							365		
Met	Lys	Lys	Leu	Ile	Asp	Ile	Arg	Asn	Gly	Lys	Gly	Glu	Val	Asp	Asp
			370			375					380				
Ile	Asp	His	Leu	Gly	Asn	Arg	Arg	Ile	Arg	Ser	Val	Gly	Glu	Met	Ala
385				390						395					400
Glu	Asn	Gln	Phe	Arg	Val	Gly	Leu	Val	Arg	Val	Glu	Arg	Ala	Val	Lys
			405						410					415	
Glu	Arg	Leu	Ser	Leu	Gly	Asp	Leu	Asp	Thr	Leu	Met	Pro	Gln	Asp	Met
			420						425				430		
Ile	Asn	Ala	Lys	Pro	Ile	Ser	Ala	Ala	Val	Lys	Glu	Phe	Phe	Gly	Ser
		435					440						445		
Ser	Gln	Leu	Ser	Gln	Phe	Met	Asp	Gln	Asn	Asn	Pro	Leu	Ser	Glu	Ile
		450				455					460				
Thr	His	Lys	Arg	Arg	Ile	Ser	Ala	Leu	Gly	Pro	Gly	Gly	Leu	Thr	Arg
465				470						475					480
Glu	Arg	Ala	Gly	Phe	Glu	Val	Arg	Asp	Val	His	Pro	Thr	His	Tyr	Gly
			485						490					495	
Arg	Val	Cys	Pro	Ile	Glu	Thr	Pro	Glu	Gly	Pro	Asn	Ile	Gly	Leu	Ile
			500						505				510		
Asn	Ser	Leu	Ser	Val	Tyr	Ala	Gln	Thr	Asn	Glu	Tyr	Gly	Phe	Leu	Glu
		515					520						525		
Thr	Pro	Tyr	Arg	Lys	Val	Thr	Asp	Gly	Val	Val	Thr	Asp	Glu	Ile	His
			530			535					540				

-continued

Tyr Leu Ser Ala Ile Glu Glu Gly Asn Tyr Val Ile Ala Gln Ala Asn
 545 550 555 560
 Ser Asn Leu Asp Glu Glu Gly His Phe Val Glu Asp Leu Val Thr Cys
 565 570 575
 Arg Ser Lys Gly Glu Ser Ser Leu Phe Ser Arg Asp Gln Val Asp Tyr
 580 585 590
 Met Asp Val Ser Thr Gln Gln Val Val Ser Val Gly Ala Ser Leu Ile
 595 600 605
 Pro Phe Leu Glu His Asp Asp Ala Asn Arg Ala Leu Met Gly Ala Asn
 610 615 620
 Met Gln Arg Gln Ala Val Pro Thr Leu Arg Ala Asp Lys Pro Leu Val
 625 630 635 640
 Gly Thr Gly Met Glu Arg Ala Val Ala Val Asp Ser Gly Val Thr Ala
 645 650 655
 Val Ala Lys Arg Gly Gly Val Val Gln Tyr Val Asp Ala Ser Arg Ile
 660 665 670
 Val Ile Lys Val Asn Glu Asp Glu Met Tyr Pro Gly Glu Ala Gly Ile
 675 680 685
 Asp Ile Tyr Asn Leu Thr Lys Tyr Thr Arg Ser Asn Gln Asn Thr Cys
 690 695 700
 Ile Asn Gln Met Pro Cys Val Ser Leu Gly Glu Pro Val Glu Arg Gly
 705 710 715 720
 Asp Val Leu Ala Asp Gly Pro Ser Thr Asp Leu Gly Glu Leu Ala Leu
 725 730 735
 Gly Gln Asn Met Arg Val Ala Phe Met Pro Trp Asn Gly Tyr Asn Phe
 740 745 750
 Glu Asp Ser Ile Leu Val Ser Glu Arg Val Val Gln Glu Asp Arg Phe
 755 760 765
 Thr Thr Ile His Ile Gln Glu Leu Ala Cys Val Ser Arg Asp Thr Lys
 770 775 780
 Leu Gly Pro Glu Glu Ile Thr Ala Asp Ile Pro Asn Val Gly Glu Ala
 785 790 795 800
 Ala Leu Ser Lys Leu Asp Glu Ser Gly Ile Val Tyr Ile Gly Ala Glu
 805 810 815
 Val Thr Gly Gly Asp Ile Leu Val Gly Lys Val Thr Pro Lys Gly Glu
 820 825 830
 Thr Gln Leu Thr Pro Glu Glu Lys Leu Leu Arg Ala Ile Phe Gly Glu
 835 840 845
 Lys Ala Ser Asp Val Lys Asp Ser Ser Leu Arg Val Pro Asn Gly Val
 850 855 860
 Ser Gly Thr Val Ile Asp Val Gln Val Phe Thr Arg Asp Gly Val Glu
 865 870 875 880
 Lys Asp Lys Arg Ala Leu Glu Ile Glu Glu Met Gln Leu Lys Gln Ala
 885 890 895
 Lys Lys Asp Leu Ser Glu Glu Leu Gln Ile Leu Glu Ala Gly Leu Phe
 900 905 910
 Ser Arg Ile Arg Ala Val Leu Val Ala Gly Gly Val Glu Ala Glu Lys
 915 920 925
 Leu Asp Lys Leu Pro Arg Asp Arg Trp Leu Glu Leu Gly Leu Thr Asp
 930 935 940
 Glu Glu Lys Gln Asn Gln Leu Glu Gln Leu Ala Glu Gln Tyr Asp Glu
 945 950 955 960

-continued

Leu Lys His Glu Phe Glu Lys Lys Leu Glu Ala Lys Arg Arg Lys Ile
 965 970 975
 Thr Gln Gly Asp Asp Leu Ala Pro Gly Val Leu Lys Ile Val Lys Val
 980 985 990
 Tyr Leu Ala Val Lys Arg Arg Ile Gln Pro Gly Asp Lys Met Ala Gly
 995 1000 1005
 Arg His Gly Asn Lys Gly Val Ile Ser Lys Ile Asn Pro Ile Glu
 1010 1015 1020
 Asp Met Pro Tyr Asp Glu Asn Gly Thr Pro Val Asp Ile Val Leu
 1025 1030 1035
 Asn Pro Leu Gly Val Pro Ser Arg Met Asn Ile Gly Gln Ile Leu
 1040 1045 1050
 Glu Thr His Leu Gly Met Ala Ala Lys Gly Ile Gly Asp Lys Ile
 1055 1060 1065
 Asn Ala Met Leu Lys Gln Gln Gln Glu Val Ala Lys Leu Arg Glu
 1070 1075 1080
 Phe Ile Gln Arg Ala Tyr Asp Leu Gly Ala Asp Val Arg Gln Lys
 1085 1090 1095
 Val Asp Leu Ser Thr Phe Ser Asp Glu Glu Val Met Arg Leu Ala
 1100 1105 1110
 Glu Asn Leu Arg Lys Gly Met Pro Ile Ala Thr Pro Val Phe Asp
 1115 1120 1125
 Gly Ala Lys Glu Ala Glu Ile Lys Glu Leu Leu Lys Leu Gly Asp
 1130 1135 1140
 Leu Pro Thr Ser Gly Gln Ile Arg Leu Tyr Asp Gly Arg Thr Gly
 1145 1150 1155
 Glu Gln Phe Glu Arg Pro Val Thr Val Gly Tyr Met Tyr Met Leu
 1160 1165 1170
 Lys Leu Asn His Leu Val Asp Asp Lys Met His Ala Arg Ser Thr
 1175 1180 1185
 Gly Ser Tyr Ser Leu Val Thr Gln Gln Pro Leu Gly Gly Lys Ala
 1190 1195 1200
 Gln Phe Gly Gly Gln Arg Phe Gly Glu Met Glu Val Trp Ala Leu
 1205 1210 1215
 Glu Ala Tyr Gly Ala Ala Tyr Thr Leu Gln Glu Met Leu Thr Val
 1220 1225 1230
 Lys Ser Asp Asp Val Asn Gly Arg Thr Lys Met Tyr Lys Asn Ile
 1235 1240 1245
 Val Asp Gly Asn His Gln Met Glu Pro Gly Met Pro Glu Ser Phe
 1250 1255 1260
 Asn Val Leu Leu Lys Glu Ile Arg Ser Leu Gly Ile Asn Ile Glu
 1265 1270 1275
 Leu Glu Asp Glu
 1280

<210> SEQ ID NO 30

<211> LENGTH: 795

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: E. coli derived thyA coding sequence

<400> SEQUENCE: 30

atgaaacagt atttagaact gatgcaaaaa gtgctcgacg aaggcacaca gaaaaacgac 60

cgtaccggaa ccggaacgct ttccattttt ggtcatcaga tgcgttttaa cctgcaagat 120

-continued

```

ggattccccg tgggtgacaac taaacggtgc cacctgcggt ccatcatcca tgaactgctg 180
tggtttctgc agggcgacac taacattgct tatctacagc aaaacaatgt caccatctgg 240
gacgaatggg ccgatgaaaa cggcgacctc gggccagtgt atggtaaaca gtggcgcgcc 300
tggccaacgc cagatggtcg tcatattgac cagatcacta cggactgaa ccagctgaaa 360
aacgaccggg attcgcgccc cattattggt tcagcgtgga acgtaggcga actggataaa 420
atggcgctgg caccgtgcca tgcattcttc cagttctatg tggcagacgg caaactctct 480
tgccagcttt atcagcgtc ctgtgacgtc ttctcggcc tgccgttcaa cattgccagc 540
tacgcggtat tgggtgcatat gatggcgagc cagtgcgac tggaagtggg tgattttgct 600
tggaccggtg gcgacacgca tctgtacagc aaccatattg atcaaaactca tctgcaatta 660
agccgcgaac cgcgtccgct gccgaagttg attatcaaac gtaaaccgga atccatcttc 720
gactaccggt tcgaagactt tgagattgaa ggctacgac cgcacccggg cattaagcgc 780
ccggtggcta tctaa 795

```

```

<210> SEQ ID NO 31
<211> LENGTH: 264
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: WT thymidylate synthase

```

```

<400> SEQUENCE: 31

```

```

Met Lys Gln Tyr Leu Glu Leu Met Gln Lys Val Leu Asp Glu Gly Thr
1          5          10          15
Gln Lys Asn Asp Arg Thr Gly Thr Gly Thr Leu Ser Ile Phe Gly His
20          25          30
Gln Met Arg Phe Asn Leu Gln Asp Gly Phe Pro Leu Val Thr Thr Lys
35          40          45
Arg Cys His Leu Arg Ser Ile Ile His Glu Leu Leu Trp Phe Leu Gln
50          55          60
Gly Asp Thr Asn Ile Ala Tyr Leu His Glu Asn Asn Val Thr Ile Trp
65          70          75          80
Asp Glu Trp Ala Asp Glu Asn Gly Asp Leu Gly Pro Val Tyr Gly Lys
85          90          95
Gln Trp Arg Ala Trp Pro Thr Pro Asp Gly Arg His Ile Asp Gln Ile
100         105         110
Thr Thr Val Leu Asn Gln Leu Lys Asn Asp Pro Asp Ser Arg Arg Ile
115         120         125
Ile Val Ser Ala Trp Asn Val Gly Glu Leu Asp Lys Met Ala Leu Ala
130         135         140
Pro Cys His Ala Phe Phe Gln Phe Tyr Val Ala Asp Gly Lys Leu Ser
145         150         155         160
Cys Gln Leu Tyr Gln Arg Ser Cys Asp Val Phe Leu Gly Leu Pro Phe
165         170         175
Asn Ile Ala Ser Tyr Ala Leu Leu Val His Met Met Ala Gln Gln Cys
180         185         190
Asp Leu Glu Val Gly Asp Phe Val Trp Thr Gly Gly Asp Thr His Leu
195         200         205
Tyr Ser Asn His Met Asp Gln Thr His Leu Gln Leu Ser Arg Glu Pro
210         215         220
Arg Pro Leu Pro Lys Leu Ile Ile Lys Arg Lys Pro Glu Ser Ile Phe
225         230         235         240

```

-continued

Asp Tyr Arg Phe Glu Asp Phe Glu Ile Glu Gly Tyr Asp Pro His Pro
 245 250 255

Gly Ile Lys Ala Pro Val Ala Ile
 260

<210> SEQ ID NO 32

<211> LENGTH: 1583

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: tehA/B operon

<400> SEQUENCE: 32

atgcagagcg ataaagtgct caatttgccg gcaggctact ttggtattgt gttggggacg 60
 atagggatgg gatttgccctg gcgctatgcc agccaggttt ggcaggtcag ccaactggta 120
 ggggatgggc tgggtattct ggcgatgatc atctggggat tattgactag cgcatttatt 180
 gcccgactca tacgctttcc gcatagcgtg ctggcggaag ttcgccatcc agtgctgagc 240
 agttttgtga gtttgtttcc ggcaacgacg atgctgggtg cgattggttt tgttccgtgg 300
 tttcgcccac tggcgggtgtg cctgttcagt tttgggtgctg tggttcagtt ggcttatgcc 360
 gcctggcaaa ctgcgggatt atggcgcgga tctcacctcg aagaagctac cacgcctgga 420
 ctgtatctgc cgacagttgc caacaacttt atcagcgcaa tggcctgtgg tgcggtgggc 480
 tacaccgacg ccggtctggt gtttttaggc gcaggcgttt tctcatggct aagccttgaa 540
 ccggtgatct tgcagcgtct gcgcagttcg ggagaattac ccacggcact gcggacatca 600
 ctcggcattc agctcgctcc tgcgctgggt gcttgtagtg cctggctgag cgtcaacggc 660
 ggcgaggggtg acacgctggc gaaaatgctt ttcggttatg gactgctgca actgctgttt 720
 atgctacgtc tgatgccatg gtatctctcc cagccattta atgcttcatt ctggagtttc 780
 tcgttcggcg tatctgcact ggcaaccacc ggtttgcac tggggagtgg cagcgataat 840
 ggatttttcc atacgctggc ggtgccgctg tttatcttta ccaattttat tattgcaata 900
 ctgctcatcc gtacttttgc gcttctgatg cagggaaaat tgtagtcag aaccgagcgc 960
 gccgttttaa tgaaagcaga ggacaaagaa tgatcattcg tgacgaaaac tattttactg 1020
 ataaatatga attaaccgc acacactctg aagtactgga agcggtgaaa gtggttaaac 1080
 cgggtaaaac gctggatctg ggctgtggca atggctgtaa cagtctttac ctggcagcca 1140
 atggttatga tgttgacgca tgggataaaa atgccatgag tatcgccaac gtcgagcgc 1200
 ttaaaccat tgaaaatctg gataatttac acaccgagt cgttgatctg aataacctca 1260
 catttgatag acagtacgat tttattcttt cgactgtggt gctgatgttc cttgaggcta 1320
 aaaccatccc cgggttgatt gccaatatgc aacgttgcac taaacctggt ggttacaacc 1380
 tgattgtggc ggcgatggat accgctgatt atccatgtac cgtcggcttc ccgtttgcct 1440
 tcaaagaggg agaattacgt cgatattacg aaggctggga gagggtgaaa tacaatgaag 1500
 acgtcggcga gctgcaccgc accgacgcca acgtaatcg tattaactg cgtttcgcca 1560
 cgatgctggc acgtaaaaaa tga 1583

What is claimed is:

1. A genetically modified bacteriophage comprising:

(i) an exogenous polynucleotide which encodes at least one agent which reduces the toxicity of a bacterium, is non-toxic to the bacterium and does not affect directly the survival of said bacterium, said polynucleotide is a dominant sensitive antibiotic resistant gene that reverses resistance of said bacterium to an antibiotic, wherein said at least one agent is 30S ribosomal subunit protein S12, encoded by the polynucleotide sequence of SEQ ID NO: 24; and

(ii) an exogenous polynucleotide which encodes a selectable marker that renders a bacterium infected by said phage resistant to a toxic compound selected from the group consisting of potassium-tellurite, chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

2. The bacteriophage of claim **1**, wherein said polynucleotide further comprises at least one dominant sensitive antibiotic resistant gene selected from the rpsl gene encoding the 30S ribosomal subunit protein S12, the gyrA gene encoding the gyrase protein, the rpoB gene that encodes the RNA Polymerase β Subunit and the thyA gene that encodes thymidylate synthase.

3. The bacteriophage of claim **2**, wherein said resistance is due to a mutated polypeptide of said bacterium selected to be 30S ribosomal subunit protein S12.

4. The bacteriophage of claim **2**, wherein said resistance is due to a mutated polypeptide of said bacterium selected to be the gyrase protein.

5. The bacteriophage of claim **2**, wherein said at least one dominant sensitive antibiotic resistant gene is a gene encoding a polypeptide selected to be 30S ribosomal subunit protein S12 or the gyrase protein.

6. The bacteriophage of claim **2**, wherein said at least one dominant sensitive antibiotic resistant gene is a gene encoding a 30S ribosomal subunit protein S12.

7. The bacteriophage of claim **1**, wherein said agent is a polynucleotide agent which down-regulates expression of an antibiotic resistance gene in said bacterium.

8. The bacteriophage of claim **1**, wherein said selectable marker comprises a resistance marker to tellurite.

9. The bacteriophage of claim **1**, being a lambda temperate phage.

10. An anti-bacterial composition, comprising a carrier and as an active ingredient the bacteriophage of claim **1**.

11. The antibacterial composition of claim **10**, formulated as a spray, a stick, a paint, a gel, a cream, wash, a wipe, a foam, a soap, an oil, a solution, a lotion, an ointment or a paste.

12. An isolated population of bacterial cells comprising the bacteriophage of claim **1**.

13. A kit comprising the phage of claim **1** and a compound which is toxic to bacteria, wherein said toxic compound is selected from the group consisting of potassium-tellurite, chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

14. A method of preventing a bacterial infection which is resistant to an antibiotic in a subject, the method comprising contacting a solid surface with an anti-bacterial composition that includes the bacteriophage of claim **1**, thereby preventing the bacterial infection.

15. The method of claim **14**, further comprising contacting the solid surface with a compound which is toxic to bacteria, said compound is selected from the group consisting of potassium-tellurite, chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

16. A genetically modified bacteriophage comprising:

(i) an exogenous polynucleotide which encodes a polypeptide which reverses resistance of a bacterium to an antibiotic, wherein said polypeptide is 30S ribosomal subunit protein S12, encoded by the polynucleotide sequence of SEQ ID NO: 24; and

(ii) an exogenous polynucleotide which encodes a selectable marker that renders a bacterium infected by said phage resistant to a toxic compound selected from the group consisting of potassium-tellurite, chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

17. A genetically modified bacteriophage comprising an exogenous polynucleotide which encodes at least one polypeptide which reverses resistance of a bacterium to an antibiotic and is non-toxic to the bacterium, wherein said wherein said at least one polypeptide is 30S ribosomal subunit protein S12, encoded by the polynucleotide sequence of SEQ ID NO: 24.

18. The bacteriophage of claim **17**, wherein said polynucleotide further comprises at least one dominant sensitive antibiotic resistant gene selected from the rpsl gene encoding the 30S ribosomal subunit protein S12, the gyrA gene encoding the gyrase protein, the rpoB gene that encodes the RNA Polymerase β Subunit and the thyA gene that encodes thymidylate synthase.

19. The bacteriophage of claim **17**, wherein said polynucleotide further comprises a dominant sensitive antibiotic resistant gene encoding a gyrase protein.

20. The bacteriophage of claim **19**, wherein said exogenous polynucleotide further encodes a selectable marker.

21. An anti-bacterial composition, comprising a carrier and as an active ingredient the bacteriophage of claim **19**.

22. A method of preventing a bacterial infection which is resistant to an antibiotic in a subject, the method comprising contacting a solid surface with an anti-bacterial composition that includes the bacteriophage of claim **19**, thereby preventing the bacterial infection.

23. A genetically modified bacteriophage comprising an exogenous polynucleotide which encodes a polypeptide which reverses resistance of a bacterium to an antibiotic, wherein said polypeptide is the 30S ribosomal subunit protein S12 and is encoded by the polynucleotide sequence of SEQ ID NO: 24.

24. The bacteriophage of claim **23**, wherein said exogenous polynucleotide further encodes a selectable marker.

25. The bacteriophage of claim **24**, wherein said selectable marker comprises a resistance marker to tellurite.

26. The bacteriophage of claim **23**, being a lambda temperate phage.

27. An anti-bacterial composition, comprising a carrier and as an active ingredient the bacteriophage of claim **23**.

28. The antibacterial composition of claim **27**, formulated as a spray, a stick, a paint, a gel, a cream, wash, a wipe, a foam, a soap, an oil, a solution, a lotion, an ointment or a paste.

29. A method of preventing a bacterial infection which is resistant to an antibiotic in a subject, the method comprising contacting a solid surface with an anti-bacterial composition that includes the bacteriophage of claim **23**, thereby preventing the bacterial infection.

30. The method of claim **29**, further comprising contacting the solid surface with a compound which is toxic to bacteria, said compound is selected from the group consisting of potassium-tellurite, chlorhexidine salts, diamidines, acridines, arsenite, arsenate and antimonite.

59

31. The method of claim **30**, wherein said exogenous polynucleotide further encodes a selectable marker that renders a bacterium infected by said phage insensitive to said toxic compound.

* * * * *

5

60